Archives (Remington Collection) October 29, 2015

CURRICULUM VITAE

GARY REMINGTON, MD, PhD, FRCP(C)

Complex Mental Illness Program Schizophrenia Division

Centre for Addiction and Mental Health 250 College Street

Toronto, Ontario M5T 1R8 Telephone: (416) 535-8501 Ext. 4750

Fax: (416) 979-4292 E-mail: gary.remington@camh.ca

Department of Psychiatry Faculty of Medicine

School of Graduate Studies, Institute of Medical Science University of Toronto

2

A. Date of CV Preparation August 12, 2015 B. Biographical Information B.1. Degrees Degree Institution Year Specialty PhD Carleton University 1977 Experimental Psychology

(Psychopharmacology) MD McMaster University 1980 Medicine FRCPC University of Toronto 1984 Psychiatry Ph.D. THESIS: Genetic and ontogenetic variations in catecholaminergic and cholinergic development: a model for hyperkinesis. B.2. Employment Position Years

Schizophrenia Lead, Division of Brain and Therapeutics University of Toronto

2010-present

Professor Department of Psychiatry, Faculty of Medicine University of Toronto

2002-present

Full-Time Faculty Insititute of Medical Science School of Graduate Studies University of Toronto

2002-present

Deputy Head, Research & Education Schizophrenia Program Centre for Addiction and Mental Health Clinician Scientist Schizophrenia Program, CAMH Campbell Research Institute, CAMH (cross-appointed)

1999-2013 1993-present 2012-present

3

Director, Medication Assessment Program for Schizophrenia (MAPS) Clinic Schizophrenia Program Centre for Addiction and Mental Health Graduate Faculty Institute of Medical Science University of Toronto

1998-2013 2002-present

Graduate Faculty Department of Psychological Clinical Science University of Toronto Scarborough

2014-present

B.3. Professional Affiliations, Activities, Awards Laughlin Fellow, American College of Psychiatrists World Health Organization Task Force on Neuroleptics Psychopharmacology Consultant Canadian Medical Protective Association

1984 1990 1993-1994

Examiner Royal College of Physicians and Surgeons of Canada

1991-1996

Psychopharmacology Panel Canadian Alliance for Research on Schizophrenia (CAROS)

1990-1996

Psychopharmacology Consultant College of Physicians and Surgeons of Ontario International Classification of Mental and Behavioural Disorders, 10th Edition (ICD-10) Field Trials, Principal Investigator Founding Member & International Advisory Board International Early Psychosis Association (IEPA) World Psychiatric Association Consensus Statement on the Use of Antipsychotic Drugs Board of Advisors, Woodbridge Hospital Singapore

1990-1991 1992 1997-present 1999 2000-present

Canadian Institutes of Health Research (CIHR) University-Industry Committee

2002-2005

4

Canadian College of Neuropsychopharmacology (CCNP) Public Relations & Liaison Committee

2002-2006

Hofmann Trust Investigator (NARSAD Research Partners Program)

2002-2003

Expert Consensus Guidelines: Optimizing Pharmacologic Treatment of Psychotic Disorders (J Clin Psychiatry 2003; 64[Suppl 12])

2003

American Psychiatric Association on Antipsychotics and Metabolic Risk

2005

DSM-V Workgroup on Apathy 2005-present

International Antipsychotic Clinically Equivalent Dose (ACE-Dose) Survey

2008-2009

Canadian Institutes of Health Research (CIHR) Behavioural Sciences B

2008-2009

Expert Consensus Guidelines: Antipsychotic Dosing (Am J Psychiatry 2010; 167:686-693)

2010

International Congress on Schizophrenia Research Program Committee

2009-2011

Canadian Optimal Medication and Prescribing Utilization Service (COMPUS) Expert Review Committee (CERC), Canadian Agency for Drugs and Technologies in Health (CADTH)

2010-2011

Paul Garfinkel Award, Best Fellowship Supervisor, University of Toronto, Department of Psychiatry

2010-2011

Pfizer Psychiatry Research Awards Committee 2011-

Scientific Advisory Council, Schizophrenia Society of Ontario (SSO) Organizing Committee, NIH-Sponsored Conference: Adipogenic and Metabolic Side Effects of Antipsychotic Drugs

2011- July, 2011

Best Poster Award (Agid O, Siu C, Potkin S, McDonald K, Remington G) European College of Neuropsychopharmacolgy, Paris, France, Sept 37, 2011

September 2011

Mel Silverman Mentorship Award 2012, Institute of Medical Science, University of Toronto

May 2012

Innovations in Neuropsychopharmacology Award, Canadian College of Neuropsychopharmacology

May 2012

5

Paul Garfinkel Award, Best Fellowship Supervisor, University of Toronto, Department of Psychiatry Japanese Society of Clinical Neuropsychopharmacology Meeting, Paul Janssen Award (Takeuchi H, Suzuki T, Remington G et al. Effects of risperidone and olanzapine on cognitive function in stable patients with schizophrenia. Schizophr Bull 2013; 39:993-998)

2012-13 November 2014

MEMBERSHIP IN PROFESSIONAL SOCIETIES: Canadian Cochrane Network (CCN) Canadian College of Neuropsychopharmacology (CCNP) Canadian Medical Association (CMA) Canadian Psychiatric Association (CPA) College of Physicians and Surgeons of Ontario (CPSO) International Early Psychosis Association (IEPA) International Network for the History of Neuropsychopharmacology (INHN) Ontario Psychiatric Association (OPA) Royal College of Physicians and Surgeons of Canada (RCPSC) Schizophrenia International Research Society (SIRS) [incl. Education, Publication Committees] AD HOC EXTERNAL REVIWER: (a) FOUNDATIONS AND GROUPS Alberta Health Services Research and Innovation Fund Canadian Diabetes Association Canadian Psychiatric Research Foundation Eli Lilly Research Foundation Fonds de la Recherche en Sante du Quebec (FRSQ) Israel Science Foundation Ontario Mental Health Foundation Medical Research Council of Canada Medical Research Council (England) National Institute of Mental Health (USA) National Medical Research Council (Singapore) Ontario Ministry of Health Wellcome Trust (England) Dean’s Fund, Department of Medicine, University of Toronto (b) JOURNALS American Journal of Psychiatry Archives of General Psychiatry Biological Psychiatry BMC Neurology BMC Psychiatry Bulletin of the World Health Organization

6

Canadian Journal of Clinical Pharmacology Canadian Journal of Psychiatry Canadian Medical Association Journal Clinical Neuropharmacology Clinical Pharmacology and Therapeutics CNS Drugs Drugs European Psychiatry Evidence Based Mental Health (British Medical Journal) Expert Opinion on Investigational Drugs Expert Opinion on Pharmacotherapy Expert Opinion on Therapeutic Targets Expert Review of Neurotherapeutics International Clinical Psychopharmacology International Journal of Neuropsychopharmacology Investigational Drugs JAMA JAMA Psychiatry Journal of Clinical Pharmacology Journal of Clinical Psychiatry Journal of Clinical Psychopharmacology Journal of Nervous and Mental Disease Journal of Psychiatry & Neuroscience Lancet Psychiatry Lancet Nature Reviews Neuropsychopharmacology Neuroscience New England Journal of Medicine Pharmacy and Therapeutics Progress in Neuro-psychopharmacology and Biological Psychiatry Psychiatry Research Psychological Medicine Schizophrenia Bulletin Schizophrenia Research

EDITORAL BOARDS: Title

Date

Journal of Clinical Psychiatry (Case and Comment Series) Compendium of Pharmaceuticals and Specialties (CPS)

1995 - 1996 1998 - 2009

Clinical Schizophrenia & Related Psychoses 2006 - Advances in Therapy Drugs in R&D Current Psychopharmacology

2008 - 2010 - 2011 -

7

C. Academic History C.1. Research Schizophrenia and its pharmacology Antipsychotics – Clinical Use in the clinical setting for schizophrenia a. Clinical trials evaluating antipsychotics b. Guidelines for dosing and choice of antipsychotic c. Refractory schizophrenia and augmentation strategies d. The evaluation of side effects e.g., weight gain, EPS e. The investigation of compliance and contributing factors Antipsychotics – Biochemical The evaluation of antipsychotics and their mechanisms of action a. Use of PET to evaluate comparative receptor binding in

the novel antipsychotics i.e., 5-HT2/D2 profile b. The evaluation of D2 occupancy and its relationship to

clinical response and D2-related side effects c. The evaluation of D2 transience and its clinical

implications d. Animal models for evaluating antipsychotic potential and

risk of side effects e. Conceptual frameworks for categorizing antipsychotics

based on mechanisms of action C.2. Research Awards (Title/Amount/Source/Duration) Principal and Co-Principal Investigator Name of Agency: Merrell Dow Pharmaceuticals Date of Award: 1987-1990 Project Title: A comparison of zuclopenthxol acetate and intramuscular

haloperidol in the treatment of acutely psychotic patients Total Amount: $154,000 PI G. Remington Co-Investigators H. Rosenblat, G. Voineskos Name of Agency: Janssen Research Foundation Date of Award: 1989-1990 Project Title: A Canadian multicenter placebo-controlled study of fixed doses of

risperidone and haloperidol in the treatment of chronic schizophrenic patients

Total Amount: $96,000 PI: G. Remington Co-PIs: G. Chouinard, B. Jones, D. Bloom, D. Addington, G. W. MacEwan,

A. Labelle, L. Beauclair

8

Name of Agency: Clarke Institute Research Fund Date of Award: 1989-1990 Project Title: The quantitative assessment of akathisia Total Amount: $1,750 PI: G. Remington Name of Agency: Ontario Mental Health Foundation (OMHF) Date of Award: 1989-1990 Project Title: The quantitative assessment of akathisia Total Award: $14,375 PI: G. Remington Name of Agency: Canadian Psychiatric Research Foundation (CPRF) Date of Award: 1989-1990 Project Title: Neuroleptic-induced movement disorders: akathisia Total Amount: $34,000 PI: G. Remington Name of Agency: Sandoz Pharmaceuticals Date of Award: 1990-1991 Project Title: A prospective randomized placebo-controlled multi-center

parallel-group comparison of the efficacy and safety of amperozide in low (1-5 mg), high (7.5-12.5 mg) dose, and haloperidol (10-30 mg) in institutionalized schizophrenics

Total Award: $200,000 Centre PI: G. Remington Name of Agency: Janssen Research Foundation Date of Award: 1991-1992 Project Title: Risperidone (R 64766) in the treatment of first admission

psychotic patients: an international, multicenter, double-blind, parallel-group study

Total Award: $35,000 Centre PI: G. Remington Name of Agency: Sandoz Pharmaceuticals Date of Award: 1992 Project Title: Synaptic transmission blockade in the hippocampus with

clozapine, an atypical neuroleptic Total Award: $7,500 Co-PIs A. Baskys, G. Remington Name of Agency: Clarke Institute Research Fund Date of Award: 1992-1993 Project Title: Insight, negative symptomatology, and neurocognitive functioning

in chronic schizophrenia Total Award: $3,000 PI: G. Remington

9

Co-PI: A. Collins Co-Investigators: K. Coulter, K. Birkett Name of Agency: Janssen Research Foundation Date of Award: 1992-1993 Project Title: Risperidone (R 64766) once daily versus twice daily in the

treatment of acute exacerbations of schizophrenia: an international, multicenter, double-blind parallel trial group trial

Total Award: $132,000 Centre PI: G. Remington Name of Agency: Janssen Research Foundation Date of Award: 1992-1993 Project Title: Clinical evaluation of the efficacy and tolerability of ritanserin as

add-on therapy to depot neuroleptics in patients with predominantly negative symptoms of chronic and sub-chronic schizophrenia

Total Award: $146,160 Centre PI: G. Remington Name of Agency: Sandoz Pharmaceuticals Date of Award: 1992-1993 Project Title: A double-blind, placebo-controlled, parallel-group rising oral dose

study of the safety, tolerability and efficacy of SDZ MAR 327 in hospitalized patients with schizophrenic disorders

Total award: $108,000 Centre PI: G. Remington Name of Agency: Janssen Research Foundation Date of Award: 1993-1994 Project Title: Risperidone (R 64766) versus haloperidol in treatment resistant

chronic schizophrenic patients: a multicenter double-blind trial Total Award: $110,000 Centre PI: G. Remington Name of Agency: Janssen Research Foundation Date of Award: 1993-1994 Project Title: Long-term safety of risperidone in the treatment of psychotic

patients: an international multicenter open label trial Total Award: $35,000 Centre PI: G. Remington Name of Agency: Zeneca Pharmaceuticals Date of Award: 1993-194 Project Title: A multicenter, double-blind, randomized, controlled, multiple

fixed dose and dose regimen comparison of seroquel (ICI 204,636) and haloperidol in the prevention of psychotic relapse in outpatients with chronic and subchronic schizophrenia

10

Total Award: $193,873 Centre PI: G. Remington Name of Agency: Ontario Mental Health Foundation (OMHF) Date of Award: 1993-1996 Project Title: Differential effects of clomipramine versus haloperidol in the

treatment of autistic disorder Total Award: $86,730 PI: G. Remington Co-PIs: L. Sloman, M. Konstantareas Name of Agency: Abbott Laboratories Date of Award: 1994-1995 Project Title: A double-blind, placebo-controlled dose response comparison of

the safety and efficacy of three doses of sertindole and three doses of haloperidol in schizophrenic patients

Total Award: $142,000 Centre PI: G. Remington Name of Agency: Abbott Laboratories Date of Award: 1994-1995 Project Title: An open label assessment of the long-term safety of sertindole in

the treatment of schizophrenic patients Total Award: $95,000 Centre PI: G. Remington Name of Agency: Sandoz Date of Award: 1994-1995 Project Title: A double-blind, parallel group, multicenter comparison of the

efficacy and tolerability profile of clozapine versus risperidone in the management of treatment resistant schizophrenia

Total Award: $125,500 PI: G. Remington Co-PI: J.-M. Azorin Name of Agency: Eli Lilly Canada, Inc. Date of Award: 1994-1996 Project Title: Olanzapine versus haloperidol and risperidone in the treatment of

schizophrenia and related psychotic disorders Total Award: $125,500 Centre PI: G. Remington Name of Agency: Janssen Research Foundation Date of Award: 1995-1997 Project Title: D2 dopamine and 5-HT2 serotonin receptor occupancy in patients

on stable doses of risperidone Total Amount: $126,4000 PI: G. Remington

11

Co-PI: S. Kapur Co-Investigators: R. B. Zipursky, M. Seeman Name of Agency: Watson Laboratories Date of Award: 1998 Project Title: Plasma loxapine levels, metabolites and clinical response Total Award: $15,000 PI: G. Remington Name of Agency: Eli Lilly Canada, Inc. Date of Award: 1998 Project Title: Zyprexa (olanzapine) in schizophrenia and related psychotic

disorders: an open-label naturalistic study Total Award: $28,000 PI: G. Remington Co-PIs: R. Dickson, E. Stip Name of Agency: Janssen Pharmaceutica Inc. Date of Award: 1998-1999 Project Title: A psychoeducation program for schizophrenia Total Award: $196,803 PI: G. Remington Co-PI: A. Collins Name of Agency: Ian Douglas Bebensee Foundation Date of Award: 1999-2000 Project Title: Switching antipsychotics: abrupt discontinuation versus overlap Total Award: $38,975 PI: G. Remington Co-Investigator: C. Shammi Name of Agency: Janssen Pharmaceutica Inc. Date of Award: 1998-1999 Project Title: Determination of D2 and 5-HT2 occupancy for risperidone depot:

a PET study Total Award: $117,360 PI: G. Remington Co-PI: S. Kapur Name of Agency: National Medical Research Council (Singapore) MH 95:03/1-14 Date of Award: 1998-1999 Project Title: Clinical characteristics and associated factors in neuroleptic-

induced akathisia Total Award: $31,100 PI: G. Remington Co-PI: S.A. Chong, R. Mahendran Name of Agency: Janssen Pharmaceutica Inc.

12

Date of Award: 1998-1999 Project Title: Risperidone depot (microspheres) in the treatment of subjects

with schizophrenia or schizoaffective disorder – an open label follow-up trial

Total Award: $24,200 Centre PI: G. Remington Name of Agency: Pfizer Canada Inc. Date of Award: 1999-2000 Project Title: The 5-HT2 and D2 receptor occupancy of ziprasidone in patients

with schizophrenia and schizoaffective disorder using PET Total Award: $248,400 PI: G. Remington Co-PI: S. Kapur Name of Agency Pfizer Canada Inc. Date of Award: 1999-2000 Project Title: Open extension study evaluating the safety and tolerability of oral

ziprasidone in the treatment of patients with schizophrenia and schizoaffective disorder

Total Award: $48,000 Centre PI: G. Remington Name of Agency: Janssen-Ortho Pharmaceutica Inc. Date of Award: 2000-2001 Project Title: Cardiovascular health risks associated with antipsychotic use Total Award: $170,843 PI: G. Remington Co-PI: T. Cohn Name of Agency: Janssen-Ortho Pharmaceutica Inc. Date of Award: 2001-2002 Project Title: Topiramate augmentation in clozapine-refractory schizophrenia Total Award: $148,400 PI: G. Remington Co-PI: T. Cohn Name of Agency: NARSAD Date of Award: 2002-2004 Project Title: Extended doing with antipsychotics: rationale and evaluation Total Award: $98,289 (US) PI: Gary Remington Co-PI: (None) Independent Investigator Award Name of Agency: Stanley Medical Research Institute Date of Award: 2002-2004 Project Title: Augmentation of clozapine partial responders with tetrabenazine Total Award: $176,637 (US)

13

PI: Gary Remington Co-PI: Shitij Kapur Name of Agency: Canadian Diabetes Association Date of Award: 2008-2011 Project Title: The direct effect of antipsychotics on glucose dysregulation Total Award: $248,000 PI: Gary Remington Co-I: T. Cohn, T. Wolever, P. Fletcher Name of Agency: Canadian Foundation for Innovation Date of Award: 2008 Project Title: Transforming care for mental illness and addiction – an

integrated approach Total Award: $15,247,686 PI: CAMH (M. Bagby, J. Cairney, T. George, L. Glicksman, S. Houle, J.

Kennedy, J. Meyer, B. Mulsant, J. Rehm, G. Remington) Name of Agency: Medicure Inc. Date of Award: 2009-2010 Project Title: 5’-phosphate-monohydrate in the treatment of tardive dyskinesia Total Award: $272,505 PI: Gary Remington Name of Agency: Schizophrenia Society of Ontario Date of Award: 2009-2011 Project Title: Evaluation of motivational deficits in schizophrenia in a virtual

environment: development of an ecologically valid assessment tool Total Award: $50,000 PI: Gary Remington Co-I: G. Foussias, K. Zakzanis Name of Agency Neurocrine Biosciences, Inc. Date of Award: 2010-2011 Project Title: A Phase 2 open–label, dose titration study to evaluate the efficacy

and safety of NBI-98854 for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder

Total Award: 192,463 PI: Gary Remington Co-I: Ofer Agid, George Foussias, M Hahn Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2011-2012 Project Title: Patterns of antipsychotic nonadherene: impact on treatment

outcome Total Award: 192,539 PI: Gary Remington Co-I: Tony George, David Streiner, George Foussias, Ofer Agid, Margaret

14

Hahn Name of Agency: CAMH AFP Date of Award: April 2011-March 2012 Project Title: A treatment algorithm for refractory and ultraresistant

schizophrenia Total Award 51,853 PI: Gary Remington Co-I: Tony George, Jeff Daskalakis, Ofer Agid, George Foussias, Margaret

Hahn Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 04.2014-03.2018 Title: Clozapine levels, clinical response, and side effects Total Award: 442,650 PI: Gary Remington Co-I: B. Pollock, D. Streiner, R. Wennberg, D. Mueller, T. Rajji, Ofer Agid,

S. Kidd, G Foussias, G. Fervaha, H. Takeuchi, J. Lee Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: Title: The role of glutathione in glutamatergic system dysregulation in

treatment-resistant schizophrenia Total Award: 787,713 PI: Ariel Graff, Gary Remington Co-I: Sofia Chavez, Vincenzo De Luca, Philip Gerretsen, Shinichiro

Nakajima Co-Investigator Name of Agency: Eli Lilly Canada Inc. Date of Award: 1996-1997 Project Title: An open label study assessing the in vivo 5-HT2 and D2 receptor

occupancy of olanzapine using PET in patients with schizophrenia Total Award: $178,000 PI: S. Kapur Co-Investigators: G. Remington, R. B. Zipursky, P. Roy, S. Houle Name of Agency: Wyeth Ayerst Canada Inc. Date of Award: 1996-1997 Project Title: Combining loxapine and cyproheptadine for unique clozapine-like

5-HT2 and D2 profile Total Award: $34,500 PI: S. Kapur Co-Investigators: R. B. Zipursky, G. Remington, S. Houle Name of Agency: Canadian Psychiatric Research Foundation (CPRF) Date of Award: 1997-1998

15

Project Title: Amoxapine as an atypical antipsychotic: a PET analysis Total Award: $30,000 PI: S. Kapur Co-Investigators: R. B. Zipursky, G. Remington Name of Agency: Eli Lilly Canada Inc. Date of Award: 1997-1999 Project Title: Acute and long-term efficacy of olanzapine in first-episode

psychotic disorders: a randomized double-blind comparison with haloperidol

Total Award: $1,742,050 PI: R. B. Zipursky Co-Investigators: S. Kapur, B. Christensen, P. Roy, G. Remington, D. Mikulis, A.

Damyanovich, J. Daskalakis, I. Epstein Name of Agency: Eli Lilly Canada Inc. Date of Award: 1997-1999 Project Title: A single site PET study to investigate the D2 and 5-HT2 occupancy

of olanzapine and the relationship to clinical outcome Total Award: $360,950 PI: R. B. Zipursky, S. Kapur Co-Investigators: B. Christensen, P. Roy, G. Remington, D. Mikulis, A. Damyanovich Name of Agency: AstraZeneca Canada Inc. Date of Award: 1999 Project Title: Investigating the prolonged receptor effects of quetiapine: a PET

study PI: S. Kapur Co-Investigators:

G. Remington, R. B. Zipursky

Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2004 (1 year) Project Title: Validation of a physical activity assessment tool for individuals

with schizophrenia Total Award: $40,617 PI: G. Faulkner Co-Investigators: T. Cohn, G. Remington Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2006 (4 years) Project Title: Strategies for gene discovery in schizophrenia Total Award: 120,683 PI: J. Kennedy Co-investigators: F. Macciardi, G. Remington, A. Wong Name of Agency: Canadian Psychiatric Research Foundation (CPRF) Date of Award: 2006 (2 years)

16

Project Title: Antipsychotic polypharmacy in schizophrenia Total Award: 80,000 PI: D. Mamo Co-investigators Bruce Christensen, Jeff Daskalakis, Gary Remington, Albert Wong,

Robert Zipursky Name of Agency: Schizophrenia Society of Ontario Date of Award: 2007 (2 years) Project Title: Randomized, controlled trial of cognitive behaviour therapy in

early psychosis Total Award: 100,000 PI: J. Addington Co-investigators Bruce Christensen, Gary Remington, Mahesh Menon, Georges

Monette Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2008-2013 (5 years) Project Title: Genetics of antipsychotic-induced weight gain Total Award: 807,430 PI: D. Mueller Co-investigators: Kennedy JL, Remington G, Cohn T, Tilvari AK Name of Agency: Pfizer Canada Inc. Date of Award: 2008-2010 Project Title: 24-hour time course of striatal dopamine D2 receptor occupancy of

ziprasidone: a PET study Total Award: 331,155 (2 years) PI: David Mamo Co-investigators: Uchida H, Ismail Z, Mulsant B, Pollock P, Remington G Date of Award: 2010-2012 Project Title: Transcranial magnetic stimulation to evaluate the role of

clozapine potentiation of GABA in the treatment of schizophrenia Total Award: 141,700 (2 years) PI: Jeff Daskalakis Co-investigators: Gary Remington, Ofer Agid, Albert Wong Name of Agency: CAMH AFP Date of Award: 2011-2013 Project Title: Electronic metabolic monitoring for patients on atypical

antipsychotics: a multi-site knowledge translation and diabetes prevention project

Total Award: 99,472 (2 years) PI: Tony Cohn Co-investigators: Gary Remington, Margaret Hahn, Guy Faulkner, Shannon Grant,

17

Ranjith Chandrasena, Howard Barbaree, Jacqueline Duncan Name of Agency: CAMH AFP Date of Award: 2011-2013 Project Title: Functional assessment and treatment planning for schizophrenia

in a virtual reality environment Total Award: 105,000 PI: Albert Wong Co-investigators: Gary Remington, George Foussias Name of Agency: Ontario Shores Pilot Research Fund Date of Award: 2011-2012 Project Title: Evaluating monitoring practices for movement disorders in

patients on antipsychotics Total Award: 7,000 PI: Jamie Kellar Co-investigators Gary Remington, Beth Sproule, Caroline Warnock Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2011-2016 Project Title: Strategies for gene discovery in schizophrenia: subphenotypes,

deep sequencing, and interactions Total Award: 791,150 PI: James Kennedy Co-investigators: Vincenzo De Luca, Arun Tiwari, Clement Zai, Daniel Mueller,

Aristotle Voineskos, Gary Remington, Albert Wong Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2011-2013 Project Title: Imaging the limbic dopamine D3 receptor in schizophrenia Total Award: 209,150 PI: Ariel Graff, David Mamo Co-Investigators: Agid O, Menon M, Remington G, Houle S Name of Agency: Schizophrenia Society of Ontario Date of Award: 2011-2013 Project Title: Deep brain stimulation for the management of treatment

refractory primary negative symptoms in schizophrenia Total Award: 100,000 PI: Jeff Daskalakis Co-Investigators: Lozano AM, Foussias G, Remington G, Voineskos A, Hamani C,

Daskalakis ZJ Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2012-2015

18

Project Title: Identifying and measuring correlates and determinants of physical activity in individuals with schizophrenia

Total Award: 200,000 PI: Guy Faulkner Co-Investigators: Arbour-Nicitopoulos KP, Cairney J, Cohn TA, Remington G, Stone M Name of Agency: Canadian Diabetes Association (CDA) Date of Award: 2012-2015 Project Title: Lifestyle interventions for the prevention and management of

diabetes in schizophrenia Total Award: 294,505 PI: Rohan Ganguli Co-Investigators: Remington G, Faulkner G, Wolever T Name of Agency: Ontario Mental Health Foundation (OMHF) Date of Award: 2013-2015 Project Title: Dissecting the heterogeneity of schizophrenia: biomarker

discovery for primary negative symptoms Total Award: 123,136 PI: Aristotle Voineskos Co-Investigators: Zakzanis K, Remington G, Foussias G, Lerch J Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: 2013-2017 Project Title: Stress-induced dopamine release in subjects at clinically high risk

for psychosis: a [11C]-FBL457 PET study Amount: 363,973 PI: Romina Mizrahi Co-Investigators: Houle S, Kenk M, Remington G, Rusjan P, Wilson A Name of Agency: CARSTAR Automotive Canada Research Innovation Fund Date of Award: 08.2013-07.2015 Project Title: A personalized medicine approach to the long-term treatment of

schizophrenia Amount: 32,000 PI: Robert Zipursky Co-Investigators Kiang M, Cook P, Agid O, Remington G, Streiner D Name of Agency: Ontario Mental Health Foundation (OMHF) Date of Award: 04.2014-03.2016 Project Title: Deconstructing motivational deficits in schizophrenia and

depression Amount: 149,940 PI: George Foussias Co-Investigators: Remington G, Ravindran A, Zakzanis K

19

Name of Agency: National Institute of Health (US) Date of Award: 07.16.14-04.30.19 Project title: Social processes initiative in the neurobiology of the

schizophrenia(s) Amount: 4,877,390 PI: Aristotle Voineskos, Anil Malhotra, Robert Buchanan, Will Carpenter Co-Investigators: George Foussias, Jim Gold, Gary Remington, Gregory Strauss, Philip

Szeszko Name of Agency: Hotchkiss Brain Institute/Matheson Centre for Mental Health

Research and Education Seed Grant Date of Award: 01.01.15-12.31.15 Project Title: Canadian clinical practice guidelines for the treatment of

schizophrenia and other psychotic disorders Amount: 40,452 PI: Donald Addington, Tamara Pringsheim Co-Investigators

Jean Addington, Zahinoor Ismail, Ross Norman, Gary Remington

Name of Agency: National Institute of Health (US) Date of Award: 01.01.14-12.31.18 Project Title: Imaging neuroinflammation in clinical high risk and

schizophrenia Amount: 1,312,692 PI: Romina Mizrahi Co-Investigators Houle S, Kenk M, Remington G, Rusjan P, Wilson A Name of Agency: Ontario Mental Health Foundation Date of Award: 02.01.15-01.31.17 Project Title: The role of glutathione in glutamatergic system dysregulation in

treatment-resistant schizoprhrenia Amount: 74,769 PI: Ariel Graff-Guerrero Co-Investigators: Gary Remington, Phil Gerretsen, Shinichiro Nakajima, Vincenzo

DeLuca, Napapon Sailusta, Mallar Chakravarty Name of Agency: Canadian Institutes of Health Research (CIHR) Date of Award: Project Title: Development, validation and benefits of a genetic risk model for

antipsychotic-induced weight gain Amount: 704,869 PI: Daniel Mueller Co-Investigators: Ana Andreazza, Vanessa Goncalves, Margaret Hahn, James Kennedy,

Gary Remington, Arun Tiwari, Clement Zai D. Presentations and Special Lectures

20

D.1. Conference Posters and Presentations 1. Remington G, Sklar LS, Anisman H. Effects of inescapable shock on subsequent escape

performance: dopaminergic mediation of response initiation and maintenance. Canadian Psychological Association, Vancouver, British Columbia, June 1977

2. Sklar LS, Remington G, Anisman H. Effects of inescapable shock on subsequent escape performance: effects of catecholaminergic manipulations. Canadian Psychological Association, Vancouver, British Columbia, June 1997

3. Remington G, Hoffman B. Gas sniffing as a form of a substance abuse. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982

4. Remington G, Jeffries JJ. Psychiatric disturbances associated with cerebral arteriovenous malformations. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982

5. Jeffries JJ, Remington G, Wilkins J. Combined lithium/neuroleptic toxicity. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982

6. Seeman M, Voineskos G, Remington G, Tourgis P, Goering P. Schizophrenia: comprehensive continuing care. Ontario Psychiatric Association 64th Annual Meeting, Toronto, Ontario, January 1984

7. Remington G, Book H. De Clerambault’s syndrome, bipolar affective disorder and response to lithium. Canadian Psychiatric Association 36th Annual Meeting, Banff, Alberta, October 1984

8. Menuck M, Remington G, Schmidt P, Legault S. Classification of functional psychoses. Ontario Psychiatric Association 65th Annual Meeting, Toronto, Ontario, January 1985

9. Rosenblat R, Tang S, Persad E, Remington G. Propranolol-antidepressant interaction. Clinical Research Society of Toronto, Toronto, Ontario, April 1985

10. Remington G, Legault S, Schmidt P, Menuck M. The nosologic status of the atypical functional psychoses. I. A clinical profile of the atypical psychoses. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985

11. Schmidt P, Legault S, Remington G, Menuck M. The nosologic status of the atypical functional psychoses II. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985

12. Legault S, Schmidt P, Remington G, Menuck M. The nosologic status of the atypical psychoses III. ‘Cycloid psychosis’ and the atypical functional psychoses. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985

13. Remington G. Neuroleptics: emergency use and current research. Conference on Practical Issues in Clinical Psychopharmacology, Toronto, Ontario, November 1985

14. Persad E, Remington G. New approaches in the pharmacotherapy of mania and depression. Ontario Psychiatric Association 66th annual Meeting, Toronto, Ontario, January 1986

15. Remington G, Pollock B, Voineskos G, Warsh J, Reed K, Beresford J, Coulter K. The emergency treatment of acutely psychotic patients: clinical and pharmacologic correlates. Fourth World Congress of Biological Psychiatry, Philadelphia, Pennsylvania, September 1986

16. Remington G, Book H. Discriminative validity of the Borderline Syndrome Index, a self-report questionnaire. Canadian Psychiatric Association 38th Annual Meeting, Vancouver, British Columbia, September 1986

21

17. Jeffries JJ, Remington G. Schizophrenia and depression. Conference on Affective Disorders: New Approaches to Investigation and Management, Toronto, Ontario, November 1988

18. Prendergast P, Turner T, Remington G. High dose, low dose, no dose - the role of medication in chronic schizophrenia. Psychiatric Rehabilitation: A National Perspective Conference, Toronto, Ontario, October 1989

19. Remington G. Symposium Chair, New perspectives in the pharmacological treatment of schizophrenic patients: role of zuclopenthixol. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990

20. Remington G, Voineskos G, Pollock B, Reed K, Coulter K, Acutely psychotic patients receiving high dose neuroleptic therapy. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990

21. Remington G, Fornazzari L, Tupling S, Rosenblat H, Coulter K, Hassell K. The quantitative assessment of akathisia. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990

22. Prendergast P, Turner T, Remington G. High dose, low dose, no dose - the role of medication in chronic schizophrenia. Canadian Psychiatric Association 40th Annual Meeting, Toronto, Ontario, September 1990

23. Fornazzari L, Remington G, Collins A, Rosenblat H, Smith I, Hassell K, Coulter K, Jeffries JJ. Dysprosodias in schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990

24. Remington G, Fornazzari L, Tupling S, Rosenblat H, Coulter K, Hassell K. The quantitative assessment of akathisia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990

25. Remington G, Voineskos G, Pollock B, Reed K, Coulter K. Incidence of neuroleptic-induced dystonia in mania versus schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990

26. Prendergast P, Remington G, Bezchlibnyk-Butler K. Neuroleptic dosing patterns in chronic schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990

27. Awad G, Cleghorn J, Schulz C, Remington G. Drug therapy in schizophrenia - variability of outcome and prediction of response. Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991

28. Chouinard G, Burns H, Remington G, Gauthier S. Assessment of drug-induced EPS. Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991

29. Fornazzari L, Remington G, Collins P, Rosenblat H, Coulter K, Smith I, Birkett K, Jeffries JJ. Impairment of emotionality in schizophrenia, a non-verbal and paralinguistic deficit in non-dominant hemisphere, Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991

30. MacEwan GW, Ancill RJ, Remington G, Jones B. Symposium on the treatment resistant psychotic patient. Canadian Psychiatric Association 41st Annual Meeting, Saskatoon, Saskatchewan, October 1991

31. Chouinard G, Jones B, Remington G, Addington D, Nair NPV, MacEwan GW. A placebo-controlled study of risperidone in the treatment of schizophrenia. American College of Neuropsychopharmacology 30th Annual Meeting, San Juan, Puerto Rico, December 1991

22

32. Jeffries JJ, del Rosario J, Remington G. Carbamazepine for schizophrenia. Ontario Psychiatric Association 72nd Annual Meeting, Toronto, Ontario, January 1992

33. Chouinard G, Jones B, Remington G, Addington D, Nair NPV, MacEwan GW. A placebo-controlled study of risperidone in the treatment of schizophrenia. 145th Annual Meeting of the American Psychiatric Association, Washington, D.C., May 1992

34. Remington G. Acute pharmacologic management: historical perspective and current guidelines - a role for zuclopenthixol. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992

35. Baskys A, Remington G, Wang S, Wojtowicz JM. Atypical neuroleptic clozapine blocks synaptic transmission in the hippocampus. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992

36. MacEwan GW, Chouinard G, Jones B, Remington G, Addington D, Nair NPV, Arnott W. A Canadian multicentre fixed-dose study of risperidone in chronic schizophrenia. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992

37. Remington G, Yassa R, Shriqui C, Chouinard C. Neuroleptic-induced movement disorders. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992

38. Jeffries JJ, Del Rosario J, Remington G, Williams R. Carbamazepine in schizophrenia. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992

39. Schacter DC, Kleinman I, Prendergast P, Remington G, Schertzer S. The effect of psychopathology on schizophrenic patients’ ability to give informed consent. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992

40. Chouinard C, Bloom D, Beauclair L, Jones B, Labelle A, Remington G, Addington D, MacEwan G, Arnott W. A Canadian multicentre placebo-controlled study of risperidone and haloperidol in chronic schizophrenic patients. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992

41. Baskys A, Remington G, Palmer E, Wojtowicz JM, Effects of clozapine (cloz), loxapine (lox) and haloperidol (hal) on synaptic transmission in the CA1 area of the hippocampus. Society for Neuroscience 22nd Annual Meeting, Anaheim, California, October 1992

42. Collins E, Remington G, Jones B. Assessment and treatment of extrapyramidal symptoms of schizophrenia: a workshop for clinicians. Ontario Psychiatric Association 73rd Annual Meeting, Toronto, Ontario, January 1993

43. Baskys A, Wang S, Remington G, Wojtowicz JM. Haloperidol and loxapine but not clozapine increase synaptic responses in the CA1 area of the rat hippocampus in vitro. 13th European Winter Conference on Brain Research. La Plagne, France, March 1993

44. Remington G, Reed K, Voineskos G, Coulter K. A double-blind comparison of zuclopenthixol acetate and haloperidol in acutely psychotic patients. The IVth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1993

45. Remington G, Pollock B, Reed K, Coulter K, Voineskos G. Plasma neuroleptic levels in patients with and without acute dystonic reactions. The IVth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1993

46. Jones B, Addington DE, Bloom D, Chouinard G, Remington G. Risperidone in chronic schizophrenia: impact on health care systems costs. 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, June 1993

23

47. Jones B, Collins E, Remington G, MacEwan W, Lieberman JA, Defining the treatment refractory schizophrenic patient. Canadian Psychiatric Association 43rd Annual Meeting, Winnipeg, Manitoba, September 1993

48. Addington DE, Bloom D, Chouinard G, Jones B, Remington G. The effect of risperidone on hospitalization in chronic schizophrenia. Canadian Psychiatric Association 43rd Annual Meeting, Winnipeg, Manitoba, September 1993

49. Chouinard G, Addington D, Bloom D, Jones B, Remington G, Albright P. Economic health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hawaii, December 1993

50. Remington G, Jeffries J, Papatheodorou G, Goldberg J. Moderator, symposium "What’s new in schizophrenia: a clinical update". Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 1994

51. Remington G. New and alternative drug treatments. Schizophrenia: recent progress and perspectives. Symposium presented at the Canadian College of Neuropsychopharmacology 17th Annual Meeting (CINP), Quebec City, Quebec, June 1994

52. Remington G, Prendergast P, Bezchlibnyk-Butler K. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994

53. Remington G. The impact of balanced serotonin-dopamine antagonism on the incidence of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994

54. Remington G. Acute treatment of psychosis. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994

55. Remington G, Collins A, Coulter K, Birkett K, Smith I. Neuropsychology of unawareness of illness in chronic schizophrenia. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994

56. Collins A, Remington G, Coulter K, Birkett K, Smith I. Insight and symptom clusters in chronic schizophrenia. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994

57. Remington G, Collins A, Coulter K, Birkett K, Smith I. Depression and negative symptoms in chronic schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994

58. Collins A, Remington G, Coulter K, Birkett K, Smith I. Insight and schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994

59. Smith I, Remington G, Collins A, Coulter K, Birkett K. Neuropsychological impairment in chronic schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994

60. Al-Jeshi A, Kapur S, Remington G, Jeffries J. Is loxapine the best available antipsychotic. Ontario Psychiatric Association 75th Annual Meeting, Toronto, Ontario, January 1995

61. Tugg L, Prendergast P, Remington G, Zipursky R. Maintenance neuroleptics in chronic schizophrenia. Ontario Psychiatric Association 75th Annual Meeting, Toronto, Ontario, January 1995

62. Zaharia MD, Ravindran AV, Griffiths J, Remington GJ, Merali Z, Anisman H. Laboratory and naturalistic stressors influence immune functioning. Society for Neuroscience 25th Annual Meeting, San Diego, California, November 1995

24

63. Malla A, Teehan M, Remington G. Risperidone: from clinical research to clinical practice. Ontario Psychiatric Association 76th Annual Meeting, Toronto, Ontario, January 1996

64. Remington G, Kapur S, Zipursky RB. Neuroleptic dosing and clinical correlates in first-episode psychosis: application of PET. Verging on Reality: The 1st International Conference on Strategies for Prevention of Early Psychosis. Melbourne, Australia, June 28-29, 1996

65. Remington G, Kapur S, Zipursky R. Pharmacotherapy of first episode psychosis. Symposium, Preventive Strategies in Early Psychosis Xth World Congress of Psychiatry, Madrid, Spain, August 23-28, 1996

66. Remington G, Prendergast P, Tugg L, Reed K, Zipursky R. Maintenance neuroleptic therapy: plasma and clinical correlates. Xth World Congress of Psychiatry, Madrid, Spain, August 23-28, 1996

67. Remington G. Novel neuroleptics, mechanisms of action, and clinical implications. Symposium, First Episode Psychosis: Treatment and Outcome. Canadian Psychiatric Association 46th Annual Meeting, Quebec City, Quebec, October 1996

68. Remington G. First episode psychosis: integrating PET and clinical data. First Episode Psychosis: an Interactive Workshop, Schizophrenia 1996 Conference, Vancouver, British Columbia, October 1996

69. Collins A, Remington G, Coulter K, Birkett K. Insight and symptom clusters in schizophrenia. Schizophrenia 1996 Conference, Vancouver, British Columbia, October 1996

70. Remington G. New horizons for schizophrenic patients. Symposium, New Horizons in Psychosis. 7th International Pan Arab Conference of Psychiatry, Beirut, Lebanon, November 1996

71. Kapur S, Remington G, Jones C, Houle S, Zipursky R. ‘Typical’ vs ‘atypical’: lessons from PET studies of 5-HT2 and D2 occupancy of antipsychotics. The VIth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1997

72. Kapur S, Remington G, Houle S, Zipursky RB. A new classification of antipsychotics based on 5-HT2/D2 receptor imaging. American Psychiatric Association 150th Annual Meeting, San Diego, California, May 1997

73. Kapur S, Jones C, Remington G. Houle S, Zipursky RB. Does loxapine plus cyproheptadine make clozapine: evidence from PET imaging. 6th World Congress of Biological Psychiatry, Nice, Frances, June 1997

74. Remington G, Teehan M, Beauséjour P. Schizophrenia: early detection, assessment, pharmacologic treatment and rehabilitation. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997

75. Remington G. Chronic schizophrenia: issues in pharmacotherapy. Symposium, Psychosis Through the Life Span: Integrating Theory and Clinical Practice. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997

76. Remington G. Clinical issues in treatment-resistant schizophrenia. Symposium, New Considerations in the Diagnosis and Management of Treatment-Resistant Schizophrenia. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997

77. Remington G, Teehan M, Lalonde P. Schizophrenia: early detection, assessment, pharmacologic treatment, and rehabilitation. Hôpital Louis-H. Lafontaine, Montreal, Quebec, October 31, 1997

25

78. Remington G, Teehan M. Decision-making in the pharmacotherapy of schizophrenia. A Patient-Based Learning Program for the Management of Schizophrenia and Related Psychotic Disorders. Montreal, Quebec, November 15, 1997

79. Kapur S, Cho R, Jones C and the Schizophrenia PET Group. Is amoxapine an atypical antipsychotic? Suggestive evidence from PET investigations of 5-HT2 and D2 receptor occupancy. American College of Neuropsychopharmacology 36th Annual Meeting, Wiakola, Hawaii, December 8-12, 1997

80. Zipursky R, Remington G and the Schizophrenia PET Group. PET investigation of olanzapine effects on 5-HT2 and D2 receptors in patients with schizophrenia. American College of Neuropsychopharmacology 36th Annual Meeting, Wiakola, Hawaii, December 8-12, 1997

81. Zipursky R, Kapur S, Jones C, Remington G, Shammi C, Houle S. Is there a “glass ceiling” to the D2 occupancy of clozapine? American College of Neuropsychopharmacology 36th Annual Meeting, Waikola, Hawaii, December 1997

82. Remington G. Symposium Chair, Schizophrenia: What is an Acceptable Outcome in 1998? With Drs. M. Seeman, L. Cortese. Ontario Psychiatric Association Annual Meeting, Toronto, January 21-24, 1998

83. Ungar T, Remington G, Keith R. ACCESS: a national program of education and consultation in psychiatry. American Association of Continuing Medical Education, San Diego, California, January 29, 1998

84. Remington G. Symposium Chair, PET Studies in Schizophrenia: Clinical Implications. With Dr. S. Kapur. Ontario Psychiatric Association Annual Meeting, Toronto, January 21-24, 1998

85. Remington G, Jeffries JJ. Treatment considerations. Workshop presented at Schizophrenia Update ’98, Scottsdale, Arizona, March 25-28, 1998

86. Remington G. New treatment options and decision-making. A Patient-Based Learning Program for the Management of Schizophrenia and Related Psychotic Disorders. Niagara-on-the-Lake, Ontario, April 25, 1998

87. Kapur S, Zipursky RB, Jones C, Remington G, Houle S. The receptor occupancy of olanzapine assessed with PET: theoretical and clinical implications. Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario, June 1998

88. Sloman L, Remington G, Konstantareas M, Parker K. Haloperidol versus clomipramine in autistic disorders. American Psychiatric Association 151st Annual Meeting, Toronto, Ontario, May 30-June 4, 1998

89. Kapur S, Lewis R, Remington G, Zipursky R. PET studies of 5-HT2 receptors in schizophrenia: implications for etiology and therapeutics. 21st Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Quebec, June 1998

90. Remington G. Schizophrenia and neuroleptics: ethical and medicolegal issues. XXIIrd International Congress on Law and Mental Health, Paris, France, July 1-3, 1998

91. Anand R, Alphs L, Azorin JM, Remington G, Péré J-J, Bourdeix I. Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone. Treatment-Resistant Schizophrenia and Beyond. London, England, July 8-9, 1998

92. Remington G. From the lab to clinical practice: what are the clinical implications? Symposium, Integrating Science with Clinical Practice to Optimize Outcome in Schizophrenia. Canadian Psychiatric Association 48th Annual Meeting. Halifax, Nova Scotia, September 1998

26

93. Remington G. Practical guidelines in the use of neuroleptics. First Episode Psychosis VI: Onset, Diagnosis, Management. Centre for Addiction and Mental Health, Clarke Site, Toronto, Ontario, October 30, 1998

94. Remington G. From the lab to clinical practice: what are the clinical implications? Symposium, Integrating Science with Clinical Practice to Optimize Outcome in Schizophrenia. Schizophrenia 1998: Reintegration in a Climate of Restraint. Toronto, Ontario, November 1998

95. Remington G. Novel antipsychotics: integrating PET data and clinical use. Symposium, Heterogeneity of Novel Antipsychotics: Implications for the Clinician. Schizophrenia 1998: Reintegration in a Climate of Restraint. Toronto, Ontario, November 1998

96. McGorry P, Remington G. Early intervention in psychosis. CNS Challenge – Beyond 2000. Barcelona, Spain, April 1999

97. Remington G. Serotonin/dopamine antagonism and atypicality: in vivo evidence using PET. Symposium: What Makes an Antipsychotic Atypical? The 152nd Annual Meeting of the American Psychiatric Association, Washington DC, May 1999 (Syllabus No. 25B, p 252)

98. Kapur S, Jones C, Seeman P, Remington G, Zipursky R. Prolonged receptor occupancy after a single dose of antipsychotics – do we really need to give these drugs everyday? American College of Neuropsychopharmacology 38th Annual Meeting, Acapulco, Mexico, December 12-16, 1999 (Syllabus No. 105, p 143)

99. Addington DE, Addington JM, Patten SB, Remington GJ, Moamai J, Labelle A, Beauclair L. Sertraline for depression in remitted schizophrenia. American Psychiatric Association, 153rd Annual Meeting, Chicago, Illinois, May 13-18, 2000

100. Remington G. Antipsychotics: integrating theory and clinical practice. Symposium Psychopharmacologie, 34e Congrès Annuel de l’AMPQ, Quebec City, Quebec, May 25-27, 2000

101. Kapur S, Wadenber M-L, Remington G, Zipursky R, Houle S. Dopamine D2 occupancy as a linking variable between animal and clinical studies of antipsychotic drugs. The 3rd International Symposium on Functional Neuroreceptor Mapping, Columbia University, New York, NY, June 2000

102. Addington D, Beauclair L, Labelle A, Moamai J, Patten S, Remington G. A double-blind, placebo-controlled comparison of sertraline for major depression in patients with remitted schizophrenia. 50th Annual Meeting of the Canadian Psychiatric Association, Victoria, British Columbia, October 3-6, 2000

103. Remington G. Antipsychotic dosing patterns in 3 treatment settings. Schizophrenia Clinical Update 2000, Toronto, Ontario, October 25-27, 2000

104. Remington G, Cohn T. Antipsychotic-related side effects. Schizophrenia Clinical Update 2000, Toronto, Ontario, October 25-27, 2000

105. Dewa CS, Remington G, Fearnley J, Goering P. A preliminary examination of trends in the use of new antipsychotic agents. Annual Meeting of the American Public Health Association, Boston, Massachusetts, November 2000

106. Cohn TA, Remington GJ, Lieter L, Kameh H. Antipsychotic medication and insulin resistance. VIIIth International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28-May 2, 2001

107. Kapur S, Zipursky RB, Remington GJ. What really is “atypical” about atypical antipsychotics: lessons from PET imaging studies. Symposium, Atypical Antipsychotic Drugs: How Do They Work? 154th Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, May 5-10, 2001

27

108. Cohn T, Remington GJ, Leiter L, Kameh H. Antipsychotic medication and insulin resistance. 154th Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, May 5-10, 2001

109. Addington D, Patten S, Remington GJ, Moamai J. Sertraline for depression in remitted schizophrenia. 7th World Congress of Biological Psychiatry, Berlin, Germany, July 1-6, 2001

110. Remington G, Collins A. Video Workshop - An educational intervention to enhance compliance in schizophrenia. 53rd Institute on Psychiatric Services, American Psychiatric Association, Orlando, Florida, October 10-14, 2001

111. Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA, and the Canadian Switch Study Group. Switching from previous antipsychotics to olanzapine: memory and executive functions in an 8-week study. 51st Annual Cnaadian Psychiatric Association Meeting, Montreal, Quebec, November 15-19, 2001

112. Meltzer H, Kane JM, Remington G, Gaebel W, Lieberman J. How much of an advance are atypicals? Neuroscience Forum, Lisbon, Portugal, April 27-30, 2002

113. Dickson R, Violata C, Smekal T, Glazer WM, Remington GJ, Stip S, Walker D, Jones B. Serial measurement of sexual function using the DGSFi in an olanzapine switch trial. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, May, 2002

114. Stip E, Remington GJ, Durson SM, Reiss JP, MacEwan GW, Chokka PR, Dickson RA, Jones B. Canadian multi-center trial assessing memory and executive function in patients with schizophrenia spectrum disorders treated with olanzapine. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, May, 2002

115. Remington G, Devos E, Eerdekens , Duchesne I, Leaf A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. XII World Congress of Psychiatry, Yokohama, Japan, August 24-29, 2002

116. Dickson R, Violata C, Smekal T, Glazer WM, Remington GJ, Stip S, Luther MF, Walker DJ, Jones B. Serial measurement of sexual function and prolactin levels in an olanzapine switch trial. 15th European College of Neuropsychopharmacology, Barcelona, Spain, October 5-9, 2002

117. Cohn T, Remington G. Cigarette smoking and diabetes in schizophrenia: evidence for an inverse correlation. IXth International Congress on Schizophrenia Research, Colorado Springs, Colorado, March 29-April 2, 2003

118. Remington G, Mamo D, Shammi C, Papatheodorou G, Mann S, Kapur S. Ziprasidone: D2 and 5-HT2 profile using PET. 156th Annual Meeting of the American Psychiatric Association, San Francisco, California, May 17-22, 2003

119. Mamo D, Hussey D, Chirakal R, Wilson A, Remington G, Nobrega J, Houle S, Kapur S. The effect of single-dose risperidone on dopamine synthesis in healthy human subjects measured using 6-[18F]-L-m-tyrosine positron emission tomography. Brain & PET 2003 Conference, Calgary, Alberta, July 2003

120. Remington G, Devos E, Eerdekens , Duchesne I, Leaf A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. European Congress of Neuropsychopharmacology (ECNP), Prague, Czech Republic, September 20-24, 2003

121. Remington G, Mamo D, Shammi C, Papatheodorou G, Mann S, Kapur S. The 5-HT2 and D3 binding profile of Ziprasidone using PET: theoretical and clinical implications. 53rd Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, October 30-November 2, 2003

28

122. Remington G. Does serotonin have a role to play in antipsychotic ‘atypicality’. Symposium, Serotonin Function: Andy Greenshaw (chair), Paul Fletcher, Pierre Blier, Gary Remington. 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, June 1, 2004

123. Remington G. Optimizing the maintenance treatment of schizophrenia. Symposium (R. Emsley, G. Remington, J. Volavka, M. Davidson), Critical Clinical Issues in the Treatment of Schizophrenia. XXIVth CINP Congress, Paris, France, June 20-24, 2004

124. Remington G. D2 and 5-HT2 profile of typical and atypical antipsychotics: PET evidence. Symposium, Dopamine-Serotonin Interactions in Psychosis and Antipsychotic Drug Actions (F. Tarazi, P. B. Bymaster, A. Y. Deutch, G. Remington). 35th Annual Meeting of the American Society for Neurochemistry, New York, New York, August 14-18, 2004

125. Zai CC, Hwang R, de Luca V, King N, Zai GC, Remington G, Kennedy JL. Evidence for association between dopamine DRD2 receptor polymorphisms and tardive dyskinesia in Caucasian schizophrenic patients. The 4th Annual Pharmacogenetics in Psychiatry Meeting, New York, New York, April 15-16, 2005

126. Cohn TA, Bois D, Remington G. Topiramate added to clozapine: metabolic effects, antipsychotic augmentation, safety, and tolerability: a 12-week, open study. 158th Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26, 2005

127. Cohn TA, Bois D, Remington G, Wolever T. First-episode and neuroleptic-free schizophrenia patients have reduced insulin sensitivity: a minimal model analysis. 158th Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26, 2005

128. Zai CC, Hwang R, DeLucai V, Muller D, King D, Zai GC, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Association study of 12 markers across DRD2 in tardive dyskinesia. XIIIth World Congress of Psychiatric Genetics, Boston Massachusetts, October 14-18, 2005

129. Remington G. Pharmacotherapy in the earliest stages of schizophrenia: too much too soon or too little too late. Symposium, Early Intervention in Schizophrenia: Biological and Psychosocial Approaches to Optimize Outcome (R Zipursky, O Agid, G Remington, A Collins, J Addington). 55th Annual Conference of the Canadian Psychiatric Association, Vancouver, British Columbia, November 3-6, 2005

130. Zai CC, De Luca V, Muller DJ, Remington G, Kennedy JL. Meta-analysis of two DRD2 polymorphisms and tardive dyskinesia in Caucasian and Asian schizophrenia patients. 5th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 7-8, 2006

131. Zai CC, De Luca V, Muller D, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association of a polymorphism 5’ of the dopamine receptor DRD3 gene in schizophrenic Caucasians with tardive dyskinesia. 11th Annual International Congress on Human Genetics, Brisbane, Australia, August 6-10, 2006

132. De Luca V, Zai C, Muller DJ, Lieberman J, Meltzer H, Remington G, Kennedy JL. Alternative strategies for quantitative trait haplotype analysis: application to MDR1 gene in tardive dyskinesia. World Psychiatric Genetics Congress XII. October 28-November 1, 2006

133. Zai CC, Romano-Silva MA, Hwang R, Zai GC, De Luca V, Muller D, Voineskos A, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphsisms in tardive dyskinesia. World Congress of Psychiatric Genetics XV, New York, New York, October 7-11, 2007

134. Faulkner G, Cohn T, Remington G. Behavioural interventions to reduce weight gain in

29

schizophrenia. World Psychiatric Association (WPA) International Congress, Melbourne, Australia, November 28-December 2, 2007

135. Tiwari AK, Zai CC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL.Lack of association of the cannibinoid receptor (CNR1) gene to tardive dyskinesia in chronic schizophrenia patients. 7th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 4-5, 2008

136. Zai CC, De Luca V, Muller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. 7th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 4-5, 2008

137. . Motivation and pleasure in the schizophrenia spectrum: findings from the prodrome. Canadian Society for Clinical Investigation (CSCI)/Clinician Investigator Trainee Association of Canada (CITAC) Meeting, Toronto, Ontario, September 24-25, 2008

138. Foussias G, Mann S, Remington G. A phenomenological study of negative symptoms in schizophrenia: amotivation and its relationship to functioning. American College of Neuropsychopharmacology (ACNP, 47th Annual Meeting, Scottsdale, Arizona, December 7-11, 2008

139. Mizrahi R, Addington J, Rusjan P, Boileau I, Pruessner J, Ng A, Remington G, Houle S, Wilson AA. Stress-induced dopamine in subjects at clinical high risk for psychosis: a [11C]-(+)-PHNO PET preliminary report. American College of Neuropsychopharmacology (ACNP), 47th Annual Meeting, Scottsdale, Arizona, December 7-11, 2008

140. Remington G (Symposium Chair) Biological and structural factors mediating schizophrenia. 12th International Congress on Schizophrenia Research (ICOSR), San Diego, California, March 28-April 1, 2009

141. Hirata Y, Souza RP, King N, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. RGS4 genes in schizophrenia: case-control and family-based studies, drug response and tardive dyskinesia. 59th Annual Meeting of the American Society of Human Genetics (ASHG), Honolulu, Hawaii, October 20-24, 2009

142. Zai CC, Tiwari AK, De Luca V, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of catechol-O-methyl-transferase in tardive dyskinesia. XVII World Congress of Psychiatric Genetics, San Diego, California, November 4-8, 2009

143. Potkin S, Agid O, Remington G, Kapur S, Watsky E, Vanderberg D, Siu C. Placebo response in antipsychotic trials: meta-regression and patient-level time course clustering analyses. American College of Neuropsychopharmacology (ACNP) 48th Annual Meeting, Hollywood, Florida, December 6-10, 2009

144. Potkin SG, Agid O, Remington G, Kapur S, Watsky E, Vanderburg D, Siu CO. Placebo response in antipsychotic trials. International Society for CNS Clinical Trials and Methodology (ISCTM) 6th Annual Meeting, Washington, DC, February 22-24, 2010

145. Zai CC, tiwari AK, Mueller DJ, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The NMDA receptor gene Grin2B in tardive dyskinesia. 9th Annual Pharmacogenetics in Psychiatry Meeting, New York, NY, April 23-24, 2010

146. Agid O, Potkin S, Remington G, Kapur S, Watsky E, Vanderburg D, Siu C. Meta-analysis of placebo response in antipsychotic trials. 163rd Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 22-26, 2010

147. Gorczynski P, Faulkner G, Cohn T, Remington G. Using photovoice to facilitate formative research involving individuals with serious mental illness (SMI). Canadian

30

Public Health Association Centenary Conference. Toronto, Ontario, June 13-16, 2010 148. Siu C, Agid O, Remington G, Kapur S, Watsky E, Vanderburg D, Potkin SG. Placebo

response in antipsychotic trials. NCDEU 50th Annual Meeting, Boca Raton, Fl, January 14-17, 2010

149. Rajji T, Uchida H, Ismail Z, Ng W, Mamo D, Remington G, Pollock B, Mulsant B. Clozapine and global cognition in schizophrenia. NCDEU 50th Annual Meeting, Boca Raton, Fl, January 14-17, 2010

150. Foussias G, Mann S, Zakzanis K, van Reekum R, Agid O, Remington G. Motivational deficits in schizophrenia: cross-sectional and longitudinal relationships with functioning. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010

151. Rajji T, Uchida H, Ismail Z, Ng W, Mamo D, Remington G, Pollock B, Mulsant B. Clozapine and global cognition in schizophrenia. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010

152. Mizrahi R, Addington J, Rusjan P, Suridjan S, Boileau I, Ng A, Pruessner J, Remington G, Houle S, Wilson A. Stress-induced dopamine release in subjects at clinical high risk for psychosis and in antipsychotic-naïve patients with psychosis: a [11C]-(+)-PHNO PET Study. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010

153. Foussias G, Voineskos AN, Miranda D, Remington G, Rajji TK, Pollock BG, Mulsant BH, Kennedy JL. Oligodendrocyte gene polymorphisms and cognitive dysfunction in schizophrenia. 18th World Congress on Psychiatric Genetics, Athens, Greece, October 3-7, 2010

154. Tiwari AK, Zai CC, Mueller DJ, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Association study of cannabinoid receptor 1 with tardive dyskinesia in schizophrenia patients. 18th World Congress on Psychiatric Genetics, Athens, Greece, October 3-7, 2010

155. Sockalingam S, Shammi C, Powell V, Remington G. Rates of hepatitis C in clozapine-treated patients with schizophrenia. 57th Academy of Psychosomatic Medicine, Marco Island, Fl, November 10-13, 2010

156. Agid O, Siu C, Potkin S, McDonald K, Remington G. Study quality and placebo response in randomized controlled trials in schizophrenia conducted 1996-2009. American Psychiatric Association 164th Annual Meeting, Honolulu, Hawaii, May 14-18, 2011

157. Agid O, Siu C, Potkin S, McDonald K, Benattia I, Remington G. Study quality and placebo response in randomized controlled trials in schizophrenia conducted 1996-2009. NCDEU 51st Annual Meeting, Boca Raton, Florida, June 13-16, 2011

158. Hahn M, Chintoh A, Lam L, Giacca A, Mann S, Fletcher P, Cohn T, Guenette MD, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. 37th Annual Harvey Stancer Research day, Toronto, Ontario, June 16, 2011

159. Foussias G, Mann S, Zakzanis K, van Reekum R, Remington G. Motivational deficits as the key predictor of cross-sectional and longitudinal functioning in schizophrenia. 37th Annual Harvey Stancer Research day, Toronto, Ontario, June 16, 2011

160. Ahuja T, Yu C, Verbrugghe S, Singh S, Remington G, Honer W. Is more better? Combination and high-dose antipsychotic therapy in patients with schizophrenia. Canadian Psychiaric Association 61st Annual Conference, Vancouver, British Columbia, October 13-15, 2011

161. Agid O, Siu C, Ziursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1996 to 2010: a systematic review and meta-analysis. American College of Neuropsychopharmacology (ACNP) 50th Annual Meeting, Waikola, Hawaii,

31

December 4-8, 2011 162. Voineskos A, Foussias G, Lerch J, Rajji T, Lobaugh N, Remington g, Kennedy J, Pollock

B, Musant B. Subtyping schizophrenia using a multimodal neuroimaging approach. American College of Neuropsychopharmacology (ACNP) 50th Annual Meeting, Waikola, Hawaii, December 4-8, 2011

163. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Wong AHC, Zakzanis KK, Zawadski J, Fletcher P, Remington G. Assessing motivation in schizophrenia in a virtual environment. Canadian College of Neuropsychopharmacology, Vancouver, British Columbia, March 24-March 26, 2012

164. Agid O, Siu CO, McDonald K, Tsoutsoullas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy (Oral)? 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

165. De Luca V, Zai C, Remington G, Kennedy JL. Effect of geographical ancestry on tardive dyskinesia. 3rd Biennial Schizophrenia International Research Conference (Poster). Florence, Italy, April 14-18, 2012

166. Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, Remington G. Examining levels of antipsychotic adherence to better undersand nonadherence in patients with schizophrenia (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

167. Agid O, Siu CO, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-analysis (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

168. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

169. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism, endocrine and inflammatory markers in healthy volunteers (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

170. McCormick P, Fletcher P, Remington G. Effects of dopamine D3 stimulation on reward learning: implications for adjunct treatment of antipsychotic-induced motivational impairment (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012

171. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012

172. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism in healthy volunteers (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012

173. Menon M, Gerretsen P, Schmitz TW, Anderson AK, Mamo DS, Korostil M, Remington G, Kapur S, Graff-Guerrero A. Self-referential abnormalities may be trait vulnerabilities for the development of delusions (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012

32

174. Fervaha G, Menon M, Gerretsen P, Graff-Guerrero A, Schmitz T, Anderson A, Kapur S, Remington G. Whole-brain patterns of functional neural connectivity with the amygdala differentiates schizophrenia patients with and without delusions of reference (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012 [Nominated for top poster].

175. Agid O, Siu C, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-analysis. American Psychiatric Association 165th Annual Meeting, Philadelphia, Pennsylvania, May 5-9, 2012

176. Agid O, Siu CO, McDonald K, Tsoutsoullas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy? American Psychiatric Association 165th Annual Meeting, Philadelphia, Pennsylvania, May 5-9, 2012

177. Caravaggio F, Suzuki T, Uchida H, Remington G, Borlido C, Pollock B, Mulsant B, De Luca V, Mamo D, Graff A. CNS half-life of ziprasidone in schizophrenia (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012

178. Fervaha G, Remington G. Whole-brain patterns of functional neural connectivity with the amygdale differentiates schizophrenia patients with and without and delusions of reference (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012

179. Guenette MDG, Remington G. Receptor binding profile of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012

180. Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ. A meta-analysis of antipsychotic dopamine D2 receptor occupancy and clinical improvement in schizophrenia (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012

181. Kennedy JL, Tiwari A, Brandl E, Chowdhury N, Zai C, Remington G. Genetic prediction of antipsychotic-induced weight gain and tardive dyskinesia: clinical application (Oral). International Congress of the Royal College of Psychiatrists. Liverpool, UK, July 10-13, 2012

182. McCormick P, Wilson V, Fletcher P, Remington G. Preliminary studies assessing the utility of the D3 receptor for treatment of motivational impairment in schizophrenia (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

183. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Wong A, Zakzanis K, Zawadski J, Fletcher P, Remington G. Assessing motivation in schizophrenia: development of a novel ecologically valid objective assessment methodology (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

184. Hahn M, Wolever T, Arenovich T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V. Remington G. Single dose administration of olanzapine: effects on glucose metabolism in healthy volunteers (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

185. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau, Pressner JC, Remington G, Houle S, Wislon AA. Increased stress-induced dopamine release in psychosis (Plenary). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

186. Guenette M, Giacca A, Hahn M, Teo C, Lam L, Chitoh A, Fletcher P, Wolever T, Cohn T, Arenovich T, Remington G. Receptor binding profile of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012 [Best Poster Award]

187. Jesus D, Digle M, Kennedy J, Remington G, Wong A, Daskalakis J. Transcranial

33

magnetic stimulation to evaluate the role of clozapine potentiation of GABA in the treatment of schizophrenia (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

188. McDonald K, Agid O, Tsoutsoulas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy (Poster)? 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

189. Fervaha G, Menon M, Gerresten P, Graff-Guerrero A, Scmitz T, Anderson A, Kapur S, Remington G. Whole-brain patterns of functional neural connectivity with the amygdale differentiates schizophrenia patients with and without delusions of reference (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012

190. Fervaha G, Remington G. Apathy and functioning in schizophrenia. 26th Annual Meeting of the Society for Research in Psychopathology. Ann Arbor, Michigan, October 4-7, 2012

191. Agid O, Siu C, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, Florida, Dec 2-6, 2012

192. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Zakzanis KK, Zawadski J, Fletcher P, Wong AHC, Remington G. Assessing motivation in schizophrenia in a virtual environment: development of a novel, ecologically valid assessment methodology. American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, Florida, Dec 2-6, 2012

193. Duncan M, Cohn T, Remington G, Cairney J, Arbour-Nicitopoulos K, Faulkner G. Item refinement for a schizophrenia specific health action processes approach questionnaire. Eastern Canada Sport and Exercise Psychology Symposium, Brock University, Ontario, March 21, 2013.

194. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. Ontario Shores Centre for Mental Health Sciences 2nd Annual Research Day, Whitby, March 22, 2013

195. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. CINP: Pharmagenomics and Personalized Medicine in Psychiatry, Jerusalem, Israel, April 21-23, 2013

196. Agid O, Siu CO, Harvey PD, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. 166th Annual American Psychiatric Association Meeting, San Francisco CA, USA, May 18-22, 2013

197. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. First Annual NeuroMetabolic Meeting, University of Toronto, Toronto, Ontario, May 21-22, 2013

198. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. Institute of Medical Science (IMS), University of Toronto, Annual Scientific Day, Toronto, May 28, 2013

199. Fervaha G, Graff-Guerrero A, Zakzanis KK, Fousssias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a trnlational model. Institute of Medical Science (IMS), University of Toronto, Annual Scientific Day, Toronto, May 28, 2013

34

200. Agid O, Siu CO, Harvey PD, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, Florida, May 28-31, 2013

201. Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G, Mimura M. Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

202. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

203. Gerretsen P. RemingtonG, Borlido C, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M. Pothier DD, Nakajima S, Caravaggio F, Deluca V, Ganguli R, Pollock BG, Graff-Guerrero A. Insight induction and anosognosia reversal in schizophrenia with caloric vestibular stimulation: a pilot proof of concept study. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

204. Fervaha G, Graff-Guerrero A, Zakzanis KK, Fousssias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a translational model. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

205. Graff-Guerrero A, Gerretsen P, Remington G, Borlido C, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo Dc, Rajji T, Mulsant BH, Deluca V, Ganguli R, Pollock BG. Universoty of Toronto Insight Psychosis Scale (UTIP) self-report and rater versions. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

206. Siddiqui I, Foussias G, Zakzanis K, Fletcher P, Remington G. Evaluation of novelty exploration and activity preference in schizophrenia using motion tracking. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013

207. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. The 12th Annual Pharmacogenetics in Psychiatry Meeting, Miami, Florida, May 31-June 1, 2013

208. Agid O, McDonald K, Siu C, Tsoutsoulas C, Wass C, Zipursky R, Foussias G, Remington G. Happiness in first-episode schizophrenia. Plenary address, 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

209. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

210. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

211. Fervaha G, Graff-Guerrero A, Zakzanis KK, Fousssias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a trnlational model. 39th Annual Harvey Stancer

35

Research Day, Department of Psychiatry, University of Toronto, June 13, 2013 212. Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G, Mimura M.

Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

213. Voineskos A, Foussias G, Lerch J, Felsky D, Remington G, Rajji T, Lobaugh N, Pollock BG, Mulsant B. Evidence for the deficit subtype of schizophrenia. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

214. Gerretsen P, Remington G, Borlido C, Hassan S, Ganguli R, Rajji TK, Mulsant BH, Deluca V, Pollock BG, Graff A. University of Toronto Insight into Psychosis Scale (UTIP) – self-report and rater version. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

215. Siddiqui I, Foussias G, Zakzanis K, Fletcher P, Remington G. Evaluation of novelty exploration and activity preference in schizophrenia using motion tracking. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

216. Generoso S, McDonald K, Agid O, Fervaha O, Foussias G, Remington G. Caregivers of patients with schizophrenia: are they happy? 39th Annual Harrvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013

217. Agid O, Siu C, Harvey PD, Zipursky RB, Remington G. Insight, treatment and recovery in first-episode schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) 11th World Congress of Biological Psychiatry, Kyoto, Japan, June 23-27, 2013

218. Siu CO, Agid O, Waye M, Brambilla C, Remington G, Harvey PD. Insight into illness and subjective quality-of-life assessment in chronic schizophrenia. 26th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 5-9, 2013

219. Agid O, Siu C, Harvey PD, Zipursky RB, Remington G. Insight, treatment and recovery in first-episode schizophrena. 26th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 5-9, 2013

220. McCormick PN, Fletcher PJ, Browne C, Wilson VS, Remington GJ. Inhibitory effects of pramipexole on conditioned reinforcement and locomotion are not mediated by dopamine D3 receptors. 43rd Annual Society for Neuroscience Meeting, San Diego, CA, November 9-13, 2013

221. Hahn M, Chintoh A, Remington G, Teo C, Mann S, Fletcher P, Cohn T, Giacca A. Weight gain independent, diabetogenic effects of olanzapine. 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Fl, December 8-12, 2013

222. Graff-Gueerero A, Fernando C, Shinichiro N, Gerretsen P, Mamo D, Remington G, Wison A. Esimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [11C]-[+]-PHNO. 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Fl, December 8-12, 2013

223. Duncan M, Arbour-Nicitopoulos K, Cairney J, Cohn T, Remington G, Faulkner G. Development and reliability testing of a health action process approach inventory for physical activity participation among individuals with schizophrenia. Society of Behavioral Medicine, Philadelphia, PA, April 23-26, 2014

224. Gerretsen P, Menon M, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A. Impaired illness awareness in schizophrenia spectrum diosrders: resting state functional connectivity. Society of Biological Psychiatry 69th Annual Scientific Meeting, New York,

36

NY, May 8-10, 2014 225. Siddiqui I, Foussias G, Fletcher PJ, Voineskos AN, Fervaha G, Zakzanis KK, Remington

G. Objective evaluation of novelty exploration and activity preference in schizophrenia. Society of Biological Psychiatry 69th Annual Scientific Meeting, New York, NY, May 8-10, 2014

226. Siu C, Agid O, Waye M, Brambilla C, Choi WK, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. American Psychiatric Association 167th Annual Meeting, May 3-7, 2014

227. Siu C, Agid O, Waye M, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Holywood, Fl, June 16-19, 2014

228. Agid O, McDonald K, Fervaha G, Foussias G, Kantor N, Remington G. Illness progression after relapse in schizophrenia: antipsychotic re-challenge in previous responders. Harvey Stancer Research Day 40th Annual Meeting, Toronto, June 19, 2014

229. Ganguli R, Hassan S, Bhamani MA, Jemkins T, Remington G, Cohn T, Agid O. Prevention of weight gain in early psychosis: a randomized controlled clinical trial of a stepped behavioural intervention. Canadian Psychiatric Association (CPA) 64th Annual Meeting, Toronto, Ontario, September 11-13, 2014

230. Kalahani-Bargis K, Foussias G, Remington G, Zakzanis K, Jeffay E. Longitudinal analysis of verbal fluency in chronic schizophrenia. National Academicy of Neuropsychology (NAN) 34th Annual Meeting, Fajardo, Puerto Rico, November 12-15, 2014

231. Agid O, Siu C, Zipursky R, Fervaha G, Foussias G, Remington G. Antipsychotic re-challenge in previous responders. 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, Arizona, December 7-11, 2014

232. Grimes KM, Zanjani A, Foussias G, Remington G, Zakzanis KK. Memory and the mediating role of task difficulty in patients with schizophrenia. Southern Ontario Neuroscience Association (SONA) Annual Meeting, McMaster Uniersity, Hamilton, Ontario, May 1, 2015

233. Takeuchi H, Lee J, Foussias G, Agid O, Remington G. Switching to clozapine using immediate vs. gradual antipsychotic discontinuation: a pilot, Double-blind, randomized, controlled trial. 2014 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), Miami, Florida, June 24, 2015

D.2 Invited Lectures The acutely psychotic patient: emergency treatment and neuroleptization. Training lectures for

McNeil Pharmaceuticals (Canada) Ltd, October 1985, February 1986, September 1986 Alopecia areata and its psychological impact. Canadian Alopecia Areata Association, Toronto,

Ontario, October 1987 Systems of pharmacotherapeutics intervention in schizophrenia. Conference on Systems of Care

for the Chronic Schizophrenic Patient, Toronto, Ontario, March 1988 Psychotropic drug use in the mentally retarded. Metropolitan Toronto Association for the

Mentally Retarded, Toronto, Ontario, March 1988 The borderline syndrome: evolution and etiology. Conference on the Characterologically

Disturbed Patient: The Challenge of the 90’s, Toronto, Ontario, November 1988

37

The residual phase of schizophrenia. Conference on Phases of Schizophrenia, Ottawa, Ontario, February 1989

Pharmacotherapy of schizophrenia: the last five years. (i) Department of Psychiatry, University of Western Ontario, London, Ontario, May

1989 (ii) Grand Rounds, Department of Psychiatry, Scarborough-Grace Hospital, Toronto,

Ontario, September 1989 (iii) Memorial University, Department of Psychiatry, Waterford Hospital, St. John’s,

Newfoundland, October 1989 (iv) Medical Staff, Centracare Hospital. Saint John, New Brunswick, October 1989 (v) Grand Rounds, Department of Psychiatry, Camp Hill Hospital, Halifax, Nova

Scotia, October 1989 Pharmacotherapy of schizophrenia. Grand Rounds, Department of Psychiatry, Toronto East

General Hospital, Toronto, Ontario, January 1990 The interface of medication and psychological treatment. Symposium on Medications and

Psychotherapy, Ontario Psychiatric Association, Toronto, Ontario, February 1990 Update on neuroleptics.

(i) Department of Psychiatry, Douglas Hospital, Montreal, Quebec, March 1990 (ii) Grand Rounds, Department of Psychiatry, Montreal General Hospital, Montreal,

Quebec, March 1990 The atypical remitting psychoses, Department of Psychiatry, Montreal General Hospital,

Montreal, Quebec, March 1990 The evolution of pharmacotherapy. Conference on Clinical Evolution in the Psychiatric Hospital.

Niagara-on-the Lake, Ontario, April 1990 The interface of psychology and psychopharmacology. Department of Psychiatry, York

University, Toronto, Ontario, May 1990, October 1990, October 1991, October 1992 Current perspectives in schizophrenia.

(i) Grand Rounds, University of Alberta, Department of Psychiatry, Alberta Hospital, Edmonton, Alberta, May 1990

(ii) Grand Rounds, University of British Columbia, Department of Psychiatry, Vancouver General Hospital, Vancouver, British Columbia, May 1990

(iii) Grand Rounds, University of British Columbia, Department of Psychiatry, Riverview Hospital, Port Coquitlam, British Columbia, May 1990

Managing the long-term side effects of neuroleptics. Conference on Integrating Health Care: A Perspective for the 90’s, Toronto, Ontario, October 1990

Mental Illness – myths and realities: two case histories. Ninth Annual Pharmacy Technicians Conference, Toronto, Ontario, November 1990

Combining medications and psychotherapy. Workshop presented by the Clinical Section of the Ontario Psychiatric Association, Toronto, Ontario, November 1990

Rational use of psychotropic medications. Pharmaceutical Manufacturers Association of Canada Education Day, Toronto, Ontario, April 1991

Psychotropic medications in developmentally handicapped children. Beverley School Professional Development Day, May 1991

The clinical value of plasma neuroleptic levels. Symposium on Drug Therapy in Schizophrenia – Variability of Outcome and Prediction of Response. Canadian College of Neuropsychopharmacology XIV Annual Meeting, June 1991

38

Clinical measurements of akathisia. Symposium on Assessment of Drug Induced EPS and Dystonic Movements. Canadian College of Neuropsychopharmacology XIV Annual Meeting, June 1991

Depot Neuroleptics. Roundtable Discussion on Issues in the Management of Chronic Schizophrenia. Cambridge, Ontario, September 20, 1991

Schizophrenia and new developments in antipsychotic drugs. Ontario Friends of Schizophrenia, Thunder Bay, Ontario, October 28, 1991

Recent developments in antipsychotic medications. Lakehead Psychiatric Hospital, Thunder Bay, Ontario, October 29, 1991

Neuroleptic-induced movement disorders. Victoria Hospital Department of Psychiatry, University of Western Ontario, London, Ontario, November 4, 1991

Pathophysiologic basis of schizophrenia: typical and atypical neuroleptics. Merrell Dow Education Day, November 5, 1991

Neuroleptics: An update. St. Michael’s Hospital, Toronto, Ontario, April 2, 1992 Neuroleptics and side effects. Community Rehabilitation Services Program, Community

Resource Consultants of Toronto, Toronto, Ontario, May 19, 1992 Current perspectives in the treatment of schizophrenia. Department of Psychiatry, University

Hospital, University of British Columbia, Vancouver, British Columbia, July 23, 1992 Novel antipsychotics in the treatment of schizophrenia: risperidone. Pharmacy Specialty Group

in Psychiatry, Canadian Society of Hospital Pharmacists, Toronto Chapter, Toronto, Ontario, October 14, 1992

A systematic approach to treatment-resistant schizophrenia. Grand Rounds, Toronto General Hospital, Toronto, Ontario, October 30, 1992

Insight, negative symptoms and neurocognitive functioning. University of Manitoba, Winnipeg, Manitoba, November 2, 1992

New and atypical neuroleptics in schizophrenia: risperidone. Selkirk Mental Health Centre, Selkirk, Manitoba, November 2, 1992

Atypical psychoses. Grand Rounds, University of Manitoba, Winnipeg, Manitoba, November 3, 1992

Risperidone in chronic schizophrenia: a US-Canadian multicentre trial. St. Thomas Psychiatric Hospital, St. Thomas, Ontario, November 4, 1992

A review of long-acting neuroleptics. Grand Rounds, London Psychiatric Hospital, London, Ontario, November 19, 1992

Strategies in the management of treatment-resistant schizophrenia. Medical Rounds, Penetanguishene Mental Health Centre, Penetanguishene, Ontario, November 20, 1992

Update on novel and atypical antipsychotics. Community Occupational Therapists and Associates, Toronto, Ontario, January 14, 1993

Pharmacotherapy of schizophrenia: an update. Ontario Psychiatric Association 73rd Annual Meeting, Toronto, Ontario, January 29, 1993

Novel antipsychotics: theoretical and clinical implications. (i) Grand Rounds, St. Mary’s Hospital, Montreal, Quebec. February 18, 1993 (ii) Grand Rounds, Douglas Hospital, Montreal, Quebec, March 11, 1993 (iii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, March 12, 1993 (iv) Grand Rounds, Department of Psychiatry, Dalhousie University, Halifax, Nova

Scotia, March 26, 1993 (v) Department of Psychiatry, Memorial University, St. John’s, Newfoundland, April

6, 1993 (vi) Grand Rounds, Waterford Hospital, St. John’s, Newfoundland, April 7, 1993

39

Understanding and treating schizophrenia in light of new advances. Brockville Psychiatric Hospital, Brockville, Ontario, March 24, 1993

Awakenings in patients with schizophrenia: the clinician’s perspective. Psychomotor and Cognitive Impairment in Schizophrenia: Assessment and Clinical Implications, Toronto, Ontario, April 3, 1993

Neuroleptic-induced movement disorders. Memorial University, St. John’s, Newfoundland, April 7, 1993

Intolerance to antipsychotic medications in schizophrenic patients: what next? London Psychiatric Hospital. London, Ontario, April 15, 1993

Neuroleptic-induced movement disorders, York Community Services, Toronto, Ontario, April 16, 1993

Novel and atypical antipsychotics. Grand Rounds, Peel Memorial Hospital, Brampton, Ontario, April 23, 1993

Understanding and treating schizophrenia in light of new advances. The Windsor Academy of Psychiatry, Windsor, Ontario, April 27, 1993

Schizophrenia – new and alternative drug treatment. Branson Hospital, Toronto, Ontario, April 28, 1993

New and alternative treatments in the pharmacotherapy of schizophrenia. Lakehead Psychiatric Hospital, Thunder Bay, Ontario, April 30, 1993

Rational management of movement disorders caused by neuroleptics. Saskatoon City Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 13, 1993

Current perspectives in schizophrenia. Royal University Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 14, 1993

Understanding and treating schizophrenia in light of new advances. Royal University Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 14, 1993

Novel and atypical neuroleptics in the treatment of schizophrenia. Greater Vancouver Mental Health Services Society, Vancouver, British Columbia, June 1, 1993

Treatment resistant schizophrenia: a systematic approach. Psychiatry Grand Rounds, Vancouver General Hospital, Vancouver, British Columbia, June 1, 1993

Recent advances in the diagnosis and management of schizophrenia. Psychiatry Grand Rounds, Mississauga Hospital, Mississauga, Ontario, June 2, 1993

Depot neuroleptics in the treatment of schizophrenia. Department of Psychiatry, Toronto General Hospital, Toronto, Ontario, June 18, 1993

Management of neuroleptic-induced movement disorders. Grand Rounds, Whitby Psychiatric Hospital, Whitby, Ontario, July 23, 1993

Schizophrenia spectrum disorders and the use of neuroleptics. Department of Psychiatry, Mount Sinai Hospital, Toronto, Ontario, July 29, 1993

Clinical perspectives of risperidone. Department of Psychiatry, Centenary Health Centre, Scarborough, Ontario, September 21, 1993

New drugs in psychiatry: an update. Ontario Friends of Schizophrenia, Toronto, Ontario, September 22, 1993

Neuroleptic side effects and newer treatments. Schizophrenia ’93: Promising Developments, Saskatoon, Saskatchewan, October 7, 1993

Rational management of movement disorders in schizophrenia. Workshop for Schizophrenia ’93: Promising Developments, Saskatoon, Saskatchewan, October 7, 1993

Movement disorders. New Perspectives on Schizophrenia: Clinical Implications, Edmonton, Alberta, October 8, 1993

40

Movement disorders in schizophrenia: cause and treatment. Workshop for New Perspectives on Schizophrenia: Clinical Implications, Edmonton, Alberta, October 8, 1993

The pharmacology of new neuroleptics. Department of Psychiatry, Toronto East General Hospital, Toronto, Ontario, October 15, 1993

Psychopharmacology of schizophrenia: an update. Department of Psychiatry, Oshawa General Hospital, Oshawa, Ontario, October 20, 1993

Neuroleptic side effects. Lederle Preceptorship Program, Toronto, Ontario, November 4, 1993 Novel and atypical antipsychotics. Department of Psychiatry, Scarborough Grace Hospital,

Scarborough, Ontario, November 5, 1993 Neuroleptic-induced movement disorders. Department of Psychiatry, Scarborough General

Hospital, Scarborough, Ontario, January 20, 1994 Chair, Symposium: What’s New in Schizophrenia: A Clinical Update. Ontario Psychiatric

Association 74th Annual Meeting, Toronto, Ontario, January 1994 Pharmacotherapy of schizophrenia: new developments. Symposium: What’s New in

Schizophrenia: A Clinical Update. Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 1994

Advances in medications for schizophrenia. Public forum “Ensuring Access to Treatment Advances in Schizophrenia: The Psychiatrist’s Role”. Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 26, 1994

The role of dopamine and serotonin in neuroleptic-induced movement disorders. (i) Department of Psychiatry, St. Mary’s Hospital, Montreal, Quebec, February 17,

1994 (ii) Department of Psychiatry, Allan Memorial Hospital, Montreal, Quebec, February

17, 1994 (iii) Department of Psychiatry, Jewish General Hospital, Montreal, Quebec, February

17, 1994 (iv) Department of Psychiatry, Montreal General Hospital, Montreal, Quebec,

February 18, 1994 Management of neuroleptic-induced movement disorders.

(i) Department of Psychiatry, Laurentian Hospital, Sudbury, Ontario, February 23, 1994

(ii) Grand Rounds, North Bay Psychiatric Hospital, North Bay, Ontario, February 24, 1994

Schizophrenia and new antipsychotic drugs. Ontario Friends of Schizophrenics, St. Catherines Chapter, St. Catherine’s, Ontario, March 2, 1994

Theoretical implications of balanced 5-HT/DA in the positive and negative symptoms of schizophrenia. Hosp. Lafontaine, Montreal, Quebec, March 15, 1994

New antipsychotic medications. Drugs and Therapeutics Update, Toronto East General Hospital, Toronto, Ontario, April 20, 1994

Serotonergic and dopaminergic antagonism in the role of novel antipsychotics. Grand Rounds, Laurentian Psychiatric Hospital, Thunder Bay, Ontario, May 2, 1994

Current treatment strategies in schizophrenia: an update for general practitioners. Thunder Bay, Ontario, May 2, 1994

Extrapyramidal Symptom Rating Scale (ESRS). Grand Rounds, Whitby Psychiatric Hospital, Whitby, Ontario, May 6, 1994

Extrapyramidal Symptom Rating Scale (ESRS) workshop for clinicians. Whitby Psychiatric Hospital, Whitby, Ontario, May 6, 1994

41

Novel antipsychotics in the treatment of schizophrenia. Mississauga Hospital, Mississauga, Ontario, May 18, 1994

Neuroleptic-induced movement disorders. Brockville Psychiatric Hospital, Brockville, Ontario, May 19, 1994

Workshop for clinicians using the Extrapyramidal Symptom Rating Scale (ESRS). Brockville Psychiatric Hospital, Brockville, Ontario, May 19, 1994

New treatments for schizophrenia. Ontario Government Pharmaceutical and Medical Supply Service Pharmacists’ Meeting 1994, Toronto, Ontario, June 1, 1994

Chair, Symposium: Reappraisal of the Role of Depot Neuroleptics. Kitchener, Ontario, June 3, 1994

The role of depot neuroleptics in the management of schizophrenia. Symposium: Reappraisal of the Role of Depot Neuroleptics. Kitchener, Ontario, June 3, 1994

The latest in antipsychotics. Psychiatry Institute for Medical Students, Toronto, Ontario, June 6, 1994

Neuroleptic-induced movement disorders. Department of Psychiatry, St. Joseph’s Hospital, Toronto, Ontario, June 7, 1994

The clinical use of novel neuroleptics. Kitchener, Ontario, June 22, 1994 The role of novel neuroleptics in refractory schizophrenia. Etobicoke, Ontario, July 4, 1994 New research in the development of neuroleptics. Schizophrenia Society of Canada 1994 Annual

Conference, Ottawa, Ontario, August 12, 1994 Chair, Symposium: Phases of Psychosis: Pharmacological Management. Schizophrenia 1994:

Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 22, 1994 Movement disorders: management and prevention. Grand Rounds, Markham Stouffville

Hospital, Markham, Ontario, September 16, 1994 Co-Chair, Ramzy Yassa Memorial Symposium: Tardive Dyskinesia 1994: Update. Canadian

Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 22, 1994 First episode psychosis: assessment and treatment. Grand Rounds, Department of Psychiatry,

Sunnybrook Hospital, Toronto, Ontario, September 30, 1994 Pharmacotherapy of schizophrenia: an update. Department of Psychiatry, The Grey Bruce

Regional Health Centre, Owen Sound, Ontario, October 6, 1994 Clinical use of novel antipsychotic agents: risperidone. Department of Psychiatry, Centenary

Hospital, Scarborough, Ontario, October 12, 1994 Risperidone: a clinical update. Whitby Psychiatric Hospital, Whitby, Ontario, October 20, 1994 Enhancing response to psychotropic medication: side effects. 2nd Annual Psychopharmacology

Clinical Day, University of Toronto, Department of Psychiatry, Toronto, Ontario, October 20, 1994

Chair, Schizophrenia Medical Seminar. Parry Sound, Ontario, October 21-23, 1994 Pharmacotherapy of schizophrenia – acute treatment. Schizophrenia Medical Seminar, Parry

Sound, Ontario, October 21-23, 1994 A look at acute management. Workshop, Schizophrenia Medical Seminar, Parry Sound, Ontario,

October 21-23, 1994 Achieving serotonergic and dopaminergic blockade: implications for schizophrenia and

depression. Mood Disorders: Current Opinion, Dalhousie University, Halifax, Nova Scotia, November 5, 1994

An update on antipsychotics. University of Toronto Health Service, Toronto, Ontario, November 7, 1994

The middle years: current medication choices. Schizophrenia: Management Strategies Across the Lifespan. Queen Street Mental Health Centre, Toronto, Ontario, December 2, 1994

42

Neuroleptics: clinical guidelines and potential drug interactions (workshop with K. Butler). Schizophrenia: Management Strategies Across the Lifespan. Queen Street Mental Health Centre, Toronto, Ontario, December 2, 1994

Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Wellesley Hospital, Toronto, Ontario, January 13, 1995

Development of new antipsychotics. (i) Kwai Chung Hospital, Hong Kong, January 23, 1995 (ii) Castle Peak Hospital, Hong Kong, January 25, 1995

The role of serotonin-dopamine antagonism in the development of novel antipsychotics. The Hong Kong College of Psychiatrists, Hong Kong, January 24, 1995

The dichotomy of schizophrenia – positive and negative symptoms: trends in management. Philippine Psychiatric Association 20th Annual Convention, Cebu, The Philippines, January 27, 1995

Approaches to evaluating and managing treatment resistant patients. Treatment Challenges in Schizophrenia. University of Pittsburgh, Pittsburgh, Pennsylvania, February 4, 1995

Development of new antipsychotics. Workshop with Dr. S. Kapur, Treatment Challenges in Schizophrenia. University of Pittsburgh, Pittsburgh, Pennsylvania, February 4, 1995

Schizophrenia and depression. Humber Memorial Hospital, Toronto, Ontario, March 7, 1995 The role of dopamine and serotonin in neuroleptic-induced EPS. Grand Rounds, Department of

Psychiatry, Calgary General Hospital, Calgary, Alberta, March 17, 1995 First episode psychosis and the evolution of schizophrenia. Grand Rounds, Department of

Psychiatry, University Hospital, University of Edmonton, Edmonton, Alberta, March 20, 1995

Neuroleptic-induced EPS: diagnosis and treatment. Community Living Program, Edmonton, Alberta, March 20, 1995

The role of dopamine and serotonin in neuroleptic-induced EPS. Grand Rounds, Department of Psychiatry, Foothills General Hospital, Calgary, Alberta, March 21, 1995

First episode psychosis and the evolution of schizophrenia. Grand Rounds, Department of Psychiatry, Foothills General Hospital, Calgary, Alberta, March 21, 1995

Schizophrenia and depression. Medical Staff, Mental Health Centre, Penetanguishene, Ontario, March 24, 1995

Neuroleptic-induced EPS: diagnosis and management. Schizophrenia Program, Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 3, 1995

First break psychosis. Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 3, 1995

Rational management of neuroleptic-induced movement disorders. Grand Rounds, Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 4, 1995

First episode psychosis and the evolution of schizophrenia. Medical Staff, Brandon Mental Health Centre, Brandon, Manitoba, April 4, 1995

Assessment of EPS and the use of the ESRS. Brandon Mental Health Centre, Brandon, Manitoba, April 4, 1995

Schizophrenia and depression. Program for Psychiatrists and Family Doctors. Toronto, Ontario, April 13, 1995

Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Department of Psychiatry, Women’s College Hospital, Toronto, Ontario, May 26, 1995

First episode psychosis. Grand Rounds, Lakehead Psychiatric Hospital, Thunder Bay, Ontario, June 1, 1995

Neuroleptic-induced EPS: diagnosis and management. Workshop, Lakehead Psychiatric

43

Hospital, Thunder Bay, Ontario, June 1, 1995 Atypical neuroleptics. Grand Rounds, Sunnybrook Health Science Centre, Toronto, Ontario,

June 2, 1995 ESRS: Extrapyramidal Symptom Rating Scale. Workshop, Sunnybrook Health Science Centre,

Toronto, Ontario, June 2, 1995 Movement disorders in schizophrenia – managing neuroleptic side effects, Atlantic Provinces

Psychiatric Association Annual Meeting, Moncton, New Brunswick, June 10, 1995 Assessment and management of neuroleptic-induced EPS. Workshop, Atlantic Provinces

Psychiatric Association Annual Meeting, Moncton, New Brunswick, June 10, 1995 Schizophrenia and depression. Psychiatry Rounds, York-Finch Hospital, Toronto, Ontario, June

20, 1995 An update on the neurobiology of psychosis. Waterford Update, Schizophrenia ’95: Improving

Quality of Life, St. John’s Newfoundland, June 23, 1995 Managing movement disorders in schizophrenia. Workshop, Waterford Update, Schizophrenia

’95: Improving Quality of Life, St. John’s Newfoundland, June 23, 1995 First episode schizophrenia – definition and prognosis. Current Issues in First Episode

Schizophrenia, London, England, July 4, 1995 Issues in the choice of neuroleptics in first episode schizophrenia. Current Issues in First Episode

Schizophrenia, London, England, July 4, 1995 Practical aspects of dosage regimens. Current Issues in First Episode Schizophrenia, London,

England, July 4, 1995 Neuroleptic, new compounds, and changing concepts. Burlington, Ontario, July 21, 1995 Newer antipsychotics in the treatment of schizophrenia. Advances in Schizophrenia: a

Roundtable Meeting, Seoul, South Korea, September 1, 1995 Schizophrenia: new theories and novel antipsychotics. Joint Annual Meeting of the Korean

Society of Biological Psychiatry & the Korean Society of Psychopharmacology, Seoul, South Korea, September 2, 1995

Advances in the pharmacotherapy of schizophrenia. Seoul National University, Seoul, South Korea, September 3, 1995

Schizophrenia: changing concepts and the development of novel antipsychotics. (i) Fukushima Medical College, Fukushima, Japan, September 5, 1995 (ii) School of Medicine, Kanazawa University, Kanazawa, Japan, September 7, 1995 (iii) School of Medicine, Keio University, Tokyo, Japan, September 8, 1995 (iv) Department of Psychiatry, University of Philippines, Manila, Philippines,

September 13, 1995 First episode schizophrenia: issues in the choice of antipsychotics. Department of Neurology &

Psychiatry, University of Santo Tomas, Manila, Philippines, September 14, 1995 The development of novel antipsychotics. Indonesia Psychiatric Society, Jakarta, Indonesia,

September 16, 1995 Clinical implications of novel antipsychotics. Dharmawangsa Study Group on Schizophrenia: a

Roundtable Meeting, Jakarta, Indonesia, September 17, 1995 Novel antipsychotics: theory and clinical implications. Semerang State Mental Hospital,

Semerang, Indonesia, September 18, 1995 The dichotomy of schizophrenia – positive and negative symptoms: trends in management. The

Psychiatric Association of Thailand, Bangkok, Thailand, September 21, 1995 Schizophrenia and depression. Grand Rounds, Queen Street Mental Health Centre, Toronto,

Ontario, September 29, 1995 Neuroleptic-induced EPS: recognition and management. Hamilton Psychiatric Hospital,

44

Hamilton, Ontario, October 11, 1995 Assessment of neuroleptic-induced EPS. Workshop, Hamilton Psychiatric Hospital, Hamilton,

Ontario, October 11, 1995 Neuroleptics: the development of novel compounds. Kitchener, Ontario, October 11, 1995 The evaluation and management of neuroleptic-induced movement disorders in first episode

psychosis. Workshop, First Episode Psychosis II: Onset, Diagnosis, Management. Clarke Institute of Psychiatry, Toronto, Ontario, October 13, 1995

Clinical issues in the management of psychosis. Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, October 16, 1995

Neuroleptics: novel compounds and their clinical application. Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, October 17, 1995

Clinical issues in the management of psychosis. Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, October 17, 1995

Neuroleptics: new compounds and changing concepts. An update for general psychiatrists. Etobicoke, Ontario, October 19, 1995

What’s new in schizophrenia: treatment and management. Psychiatry Rounds, Department of Psychiatry, University of Alberta, Edmonton, Alberta, October 23, 1995

The role of zuclopenthixol in the management of psychosis. Department of Psychiatry, University of Alberta, Edmonton, Alberta, October 23, 1995

What’s new in schizophrenia: treatment and management. Psychiatry Rounds, Department of Psychiatry, University of Calgary, Calgary, Alberta, October 24, 1995

The management of acute psychosis. Emergency Psychiatry Workshop, Departments of Psychiatry and Emergency Medicine, University of Calgary, Calgary, Alberta, October 24, 1995

Recent developments in schizophrenia. Conference on Schizophrenia and the Family, Canadian Mental Health Foundation, New Brunswick Division. (i) Moncton, New Brunswick, October 25, 1995 (ii) St. John, New Brunswick, October 26, 1995 (iii) Fredericton, New Brunswick, October 27, 1995

Schizophrenia: changing concepts and the development of novel antipsychotics. (i) Department of Psychiatry, St. John Regional Hospital, St. John, New Brunswick,

October 26, 1995 (ii) Department of Psychiatry, Dr. Everett Chalmer’s Hospital, Fredericton, New

Brunswick, October 27, 1995 Managing schizophrenia: the physician’s role. A Clinical Day on the Management of the

Seriously Mental Ill in the Community. North Bay General Hospital, North Bay, Ontario, November 8, 1995

New developments in the treatment of schizophrenia. North Bay Medical Society, North Bay, Ontario, November 8, 1995

Phases of psychosis: pharmacologic considerations. Whitby, Ontario, November 14, 1995 Identification and management of neuroleptic-induced EPS. Department of Psychiatry, Toronto

East General Hospital, Toronto, Ontario, November 22, 1995 What’s new in the treatment of schizophrenia. Conference on Schizophrenia: Enhancing

Partnership in Treatment Compliance, Whitby Mental Health Centre, Whitby, Ontario, November 24, 1995

Dopamine and serotonin receptor mechanisms in the action of atypical antipsychotics. Conference on Schizophrenia 95, Montreal, Quebec, December 1, 1995

The role of zuclopenthixol acetate in acute psychosis. Clarke Institute of Psychiatry, Toronto,

45

Ontario, December 2, 1995 Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Department of

Psychiatry, University of Ottawa, Ottawa, Ontario, December 20, 1995 Pharmacotherapy of schizophrenia: from first episode to chronic treatment. Grand Rounds,

Department of Psychiatry, Queen’s University, Kingston, Ontario, January 19, 1996 Schizophrenia: current treatment and research. Comcare Canada, Toronto, Ontario, February 22,

1996 Evolution of antipsychotics: changing concepts and the development of new compounds.

Veterans’ General Hospital, Tapei, Taiwan, March 26, 1996 Schizophrenia: changing concepts and the development of novel antipsychotics.

(i) Taiwan Psychiatric Society, Tapei, Taiwan, March 26, 1996 (ii) Kaohsung Psychiatric Society, Kaohsung, Taiwan, March 27, 1996 (iii) Veterans’ General Hospital, Taichung, Taiwan, March 28, 1996

Pharmacologic management of first episode schizophrenia. Indonesian Psychiatric Society, Jakarta, Indonesia, March 30, 1996

Practical issues in the pharmacotherapy of schizophrenia. Darmawangsa Hospital, Jakarta, Indonesia, March 30, 1996

Pharmacotherapy of schizophrenia: from theory to clinical practice. (i) Surabaya Psychiatric Society, Surbaya, Indonesia, March 30, 1996 (ii) Yogyakarta Psychiatric Society, Jakarta, Indonesia, April 1, 1996 (iii) Medan Psychiatric Society, Medan, Indonesia, April 2, 1996

Schizophrenia: changing concepts and the development of novel antipsychotics. Department of Psychiatry. Dalhousie University, Halifax, Nova Scotia, April 10, 1996

Standard and novel neuroleptics: clinical guidelines. (i) St. Mary’s Hospital, Montreal, Quebec, April 11, 1996 (ii) The Douglas Hospital, Montreal, Quebec, April 11, 1996 (iii) Jewish General Hospital, Montreal, Quebec, April 11, 1996

Standard and novel neuroleptics: theory and clinical guidelines. Managing Severe Mental Illness – A Day in Schizophrenia, Sudbury, Ontario, May 11, 1996

Neuroleptic-induced EPS: diagnosis and management. Workshop presented at Managing Severe Mental Illness – A Day in Schizophrenia, Sudbury, Ontario, May 11, 1996

Negative symptoms in schizophrenia. Ontario Friends of Schizophrenics – East York Chapter, Toronto East General Hospital, Toronto, Ontario, May 14, 1996

Managing the aggressive patient. Kitchener, Ontario, May 16, 1996 Advances in neuroleptic therapy. Department of Psychiatry, The Toronto Hospital, Toronto,

Ontario, May 17, 1996 Past and present neuroleptics. The Medications Used to Treat Schizophrenia: Past, Present and

Future. Credit Valley Hospital, Toronto, Ontario, May 21, 1996 Managing the agitated and violent schizophrenic patient. Séminaire Médical en Psychiatrie,

L’Association des Médecins Psychiatres du Québec, Stowe, Vermont, May 24-26, 1996 The use of zuclopenthixol acetate in the management of acute psychosis. Mississauga, Ontario,

May 28, 1996 Neuroleptics: new compounds and changing concepts. Calgary 1996 Schizophrenia Conference,

Calgary, Alberta, June 4, 1996 Neuroleptic-induced movement disorders. Workshop presented at Calgary 1996 Schizophrenia

Conference, Calgary, Alberta, June 4, 1996 Neuroleptic-induced movement disorders; diagnosis and management. Riverview Hospital 2nd

Annual Schizophrenia Conference, Riverview Hospital, British Columbia, June 5, 1996

46

The management of agitated and violent psychotic patients. Oakville, Ontario, June 20, 1996 Treatment-resistant schizophrenia: pharmacotherapy. West End Mental Health Team, Greater

Vancouver Mental Health Service Society, Vancouver, British Columbia, October 8, 1996

Treatment-resistant schizophrenia. Workshop, management of treatment-resistant mental illness. The Fourth Annual Clinical Psychopharmacology Day, University of Toronto, Toronto, Ontario, October 17, 1996

Newer neuroleptics in the treatment of schizophrenia. Psychiatry Rounds, St. Joseph’s Hospital, Toronto, Ontario, October 22, 1996

Pharmacotherapy of schizophrenia: practical guidelines. Annual Clinic Day: Family Practice Update, North York Branson Hospital, Toronto, Ontario, October 23, 1996

Neuroleptics 2000: practical guidelines after fifty years experience. Mental Health Centre, Penetanguishene, Ontario, November 20, 1996

Neuroleptic-induced movement disorders: assessment and treatment. Medical Rounds, Mental Health Centre, Penetanguishene, Ontario, November 20, 1996

Pharmacotherapy of first episode psychosis. The Hospital for Sick Children 2nd Annual Psychopharmacology Day, Toronto, Ontario, November 21, 1996

Novel neuroleptics, mechanisms of action, and clinical implications. Biannual Meeting of the Ontario Provincial Hospitals’ Directors of Pharmacy, Queen Street Mental Health Centre, Toronto, Ontario, November 21, 1996

Novel neuroleptics, mechanisms of action, and clinical implications. Psychiatry Rounds, Women’s College Hospital, Toronto, Ontario, November 29, 1996

Novel neuroleptics, mechanisms of action, and clinical implication. Grand Rounds, Department of Psychiatry, Wellesley-St. Michael’s Hospital, Toronto, Ontario, December 6, 1996

New developments in the psychopharmacological treatment of schizophrenia. ‘First Episode Psychosis III: Onset, Diagnosis, Management’ Conference, Clarke Institute of Psychiatry, Toronto, Ontario, January 22, 1997

Practical guidelines in the use of neuroleptics. . ‘First Episode Psychosis III: Onset, Diagnosis, Management’ Conference, Clarke Institute of Psychiatry, Toronto, Ontario, January 22, 1997

Assessment and management of neuroleptic-induced EPS. (i) Psychiatry Grand Rounds, St. Mary’s Hospital, Montreal, Quebec, January 23,

1997 (ii) Grand Rounds, Douglas Hospital, Montreal, Quebec, January 23, 1997 (iii) Psychiatry Grand Rounds, Montreal General Hospital. Montreal, Quebec, January

25, 1997 Assessment, diagnosis and early intervention in schizophrenia. Vancouver, British Columbia,

March 5, 1997 Psychotic illness and the therapeutic alliance. Greater Vancouver Mental Health Service Society

Staff Day, Vancouver, British Columbia, March 6, 1997 Assessment and management of neuroleptic-induced EPS. Psychiatry Grand Rounds, Royal

University Hospital, Saskatoon, Saskatchewan, March 7, 1997 Standard and novel antipsychotics: theory and clinical guidelines, Remington G, Teehan M.

Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, March 7, 1997

Schizophrenia: early detection and diagnosis. ‘Waterford Update – Schizophrenia 97’ Conference. Waterford Hospital, St. John’s. Newfoundland, March 10, 1997

Assessment and management of neuroleptic-induced EPS. ‘Waterford Update – Schizophrenia

47

97’ Conference. Waterford Hospital, St. John’s. Newfoundland, March 10, 1997 Pharmacotherapy and early intervention: integrating theory and clinical practice. ‘Waterford

Update – Schizophrenia 97’ Conference. Waterford Hospital, St. John’s. Newfoundland, March 10, 1997

Advances in the pharmacotherapy of schizophrenia. Psychiatry Rounds, York-Finch Hospital, Toronto, Ontario, March 12, 1996

Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Queen Street Mental Health Centre, Toronto, Ontario, March 14, 1997

Schizophrenia I. Early detection and diagnosis, Remington G, Teehan M. Canadian Psychiatric Association 1997 International CME Program, Ixtapa, Mexico, March 18-22, 1997

Schizophrenia II: Intervention – initiating treatment and psychosocial rehabilitation. Remington G, Beausejour P. Canadian Psychiatric Association 1997 International CME Program, Ixtapa, Mexico, March 18-22, 1997

Phases of psychosis: acute and long-term pharmacotherapy. Department of Nursing, Clarke Institute of Psychiatry, Toronto, Ontario, March 27, 1997

First episode psychosis: diagnosis, treatment, and the role of new antipsychotics. ‘New developments in Treatment of Early Psychosis’Conference. In conjunction with the University of British Columbia and the Greater Vancouver Mental Health Services, Vancouver, British Columbia, April 8, 1997

Assessment and management of neuroleptic-induced EPS. Prince George Regional Hospital, Prince George, British Columbia, April 9, 1997

Schizophrenia: new theories and novel antipsychotics. Prince George Regional Hospital, Prince George, British Columbia, April 9, 1997

Advances in the pharmacotherapy of schizophrenia. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, April 18, 1997

Schizophrenia: new theories and novel antipsychotics. Psychiatry Meeting, Guelph, Ontario, April 23, 1997

Early Intervention in Schizophrenia Symposium, Chair, Toronto, May 30, 1997 Assessment, diagnosis and early intervention in schizophrenia. 3rd Annual Schizophrenia

Conference, Riverview Hospital, Port Coquitlam, British Columbia, June 4, 1997 Schizophrenia: new theories and novel antipsychotics. Victoria ’97 Schizophrenia Conference,

Victoria, British Columbia, June 5, 1997 Pharmacotherapy of schizophrenia: practical guidelines. Workshop, Victoria ’97 Schizophrenia

Conference, Victoria, British Columbia, June 5, 1997 Phases of psychosis: pharmacological management.

(i) Selkirk Mental Health Centre, Winnipeg, Manitoba, June 12, 1997 (ii) Winnipeg Health Sciences Centre, Department of Psychiatry, Winnipeg,

Manitoba, June 12, 1997 (iii) Department of Psychiatry, St. Boniface, Winnipeg, Manitoba, June 12, 1997 (iv) Psychiatry Rounds, Grey Nuns Hospital, Edmonton, Alberta, June 13, 1997 (v) Psychiatry Rounds, Mesericordia Hospital, Edmonton, Alberta, June 13, 1997 (vi) Alberta Hospital, Ponaka, Alberta, June 13, 1997

Advances in the pharmacology of schizophrenia. Toronto, Ontario, June 17, 1997 Novel versus conventional neuroleptics: do they differ clinically? Development of New

Chemical Entities for Schizophrenia. Saint-Jean-Cap-Ferrat, France, June 20-21, 1997 Newer antipsychotics in the treatment of schizophrenia: clinical update on olanzapine. Queen

Street Mental Health Centre, Toronto, Ontario, July 10, 1997 Advances in the pharmacotherapy of schizophrenia. Oshawa General Hospital, Oshawa, Ontario,

48

August 13, 1997 New developments in the psychopharmacological treatment of schizophrenia. Psychiatry

Research Seminars, The Toronto Hospital, Toronto, Ontario, September 22, 1997 Pharmacotherapy of schizophrenia: practical guidelines.

(i) Grand Rounds, Douglas Hospital, Montreal, Quebec, September 25, 1997 (ii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, September 26,

1997 (iii) Psychiatry Rounds, Jewish General Hospital, Montreal, Quebec, September 26,

1997 Will novel antipsychotics be the next standard of care for patients with schizophrenia? 2.

Pharmacotherapy of first episode psychosis. 3. Long-term treatment of schizophrenia: theory and clinical practice. Schizophrenia – Looking into the Next Millennium, Vilnius, Lithuania, October 16, 1997

Schizophrenia update. Sault Area Hospitals, Department of Psychiatry, Sault, Ste. Marie, Ontario, October 22, 1997

Advances in the psychopharmacology of schizophrenia. North Bay Psychiatric Hospital, North Bay, Ontario, October 23, 1997

The pharmacological treatment of schizophrenia. Schizophrenia Days 1997, Stavanger, Norway, November 7, 1997

Clinical guidelines for schizophrenia: a Canadian perspective. Clinical Guidelines and Psychiatry: The American and Canadian Perspectives, Montreal, Quebec, November 14, 1997

Assessment and management of neuroleptic-induced EPS, XVIIIe Congrés Annuel – Société de Psychogératrie du Québec, Hôpital Ste-Anne, Montreal, Quebec, September 5, 1997

Standard and novel neuroleptics: theory and clinical guidelines. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, December 11, 1997

The pharmacology of atypical antipsychotics. Schizophrenia Update, Toronto, Ontario, January 31, 1998

Clinical issues in treatment resistance schizophrenia. Treatment Resistance Schizophrenia: Diagnosis and Management, North Bay, Ontario, February 6, 1998

New developments in the psychopharmacological treatment of schizophrenia. (i) St. Mary’s Hospital, Montreal, Quebec, February 12, 1998 (ii) Douglas Hospital, Montreal, Quebec, February 12, 1998 (iii) Montreal General Hospital, Montreal, Quebec, February 12, 1998

Comparison of novel antipsychotics. Toronto, Ontario, February 28, 1998 Standard and novel neuroleptics: theory and clinical guidelines.

(i) Riverview Hospital, Port Coquitlam, British Columbia, March 11, 1998 (ii) Vancouver, British Columbia, March 11, 1998

Novel agents in schizophrenia. Schizophrenia Update ’98, Scottsdale, Arizona, March 28, 1998 Current issues in the pharmacotherapy of schizophrenia. Schizophrenia: Improving Functional

Outcome, Toronto, Ontario, April 2, 1998 Assessment of movement disorders. Workshop presented at Schizophrenia: Improving

Functional Outcome, Toronto, Ontario, April 2, 1998 Issues in the acute and long-term pharmacotherapy of schizophrenia. Peterborough, Ontario,

April 8, 1998 Standard and novel neuroleptics: theory and clinical guidelines. London, Ontario, April 14, 1998 New antipsychotic agents. Mississauga, Ontario, April 21, 1998 Pharmacology of atypical antipsychotics. Department of Psychiatry, York County Hospital,

49

Newmarket, Ontario, May 2, 1998 First episode psychosis: the role of novel antipsychotics. International Delegates Program,

American Psychiatric Association 151st Annual Meeting, Toronto, May 30 – June 4, 1998 Will novel antipsychotics be the next standard of care in schizophrenia? Treatment strategies in

the management of schizophrenia. (i) Istanbul, Turkey, June 15, 1998 (ii) Izmir, Turkey, June 16, 1998 (iii) Bakirkoy Mental Hospital, Istanbul, Turkey, June 17, 1998

Antipsychotics: exploration of the novel antipsychotics. Program of Advances Psychopharmacology of Psychiatrists. Clarke Institute of Psychiatry, Toronto, Ontario: (i) June 24, 1998 (ii) January 27, 1999

Pharmacotherapy in schizophrenia – an update. Schizophrenia 98: Identification, Intervention and Pharmacotherapy. Waterford Hospital, St. John’s, Newfoundland, September 25, 1998

Decision making in clinical use of antipsychotics (workshop). Schizophrenia 98: Identification, Intervention and Pharmacotherapy. Waterford Hospital, St. John’s, Newfoundland, September 25, 1998

Pharmacotherapy in the early stages of psychosis. NATO Advanced Research Workshop: Early Intervention on Psychiatric Disorders. Prague, Czech Republic, October 22 -–27, 1998

Pharmacotherapy of first episode schizophrenia. Bulgarian Psychiatric Association Annual Meeting, Sofia, Bulgaria, November 6 – 8, 1998

Psychosis and the new antipsychotic. General Psychiatry for Family Physicians (GPFP) Seminar Series 1998/99, Centre for Addiction and Mental Health, The Clarke, Toronto, Ontario, November 18, 1988

New developments in the psychopharmacologic treatment of schizophrenia. (i) Medical Staff Quarterly Meeting, Queensway Carleton Hospital, Ottawa, Ontario,

December 7, 1998 (ii) Psychiatric Rounds, Queensway Carleton Hospital, Ottawa, Ontario, December 8,

1998 (iii) Grand Rounds, Royal Ottawa Hospital, Ottawa, Ontario, December 8, 1998

Long-acting antipsychotics and the role of the depot clinic. Conference, Difficult to Serve Psychiatric Populations: Aspects of Community Care. North Bay, Ontario, February 11-12, 1999

Clozapine vs risperidone in refractory schizophrenia. Maximizing Optimum Treatment in the Expanding Age of Treatment Resistant Schizophrenia. St.-Sauveur, Quebec, February 26 – 28, 1999

Pharmacotherapy of schizophrenia: an update. (i) Edmonton, Alberta, March 9, 1999 (ii) Psychiatry Rounds, Alberta Hospital, Ponoka, Alberta, March 10, 1999 (iii) Red Deer, Alberta, March 10, 1999 (iv) Psychiatry Rounds, University of Saskatchewan, Regina, Saskatchewan, March

11, 1999 (v) Psychiatry Rounds, University of Saskatchewan, Saskatoon, Saskatchewan,

March 12, 1999 Assessment and treatment of neuroleptic-induced EPS. Whitby Mental Health Centre. Whitby,

Ontario, March 26, 1999 Addressing compliance to optimize clinical outcome. A Patient-Based Learning Program in

50

Schizophrenia and Related Psychotic Disorders. Toronto, Ontario, March 27, 1999 Conventional and novel antipsychotics: theoretical and clinical guidelines. Mental Health

Services, Brantford, Ontario, April 28, 1999 Antipsychotics and schizophrenia: from science to clinical practice. Grand Rounds, Department

of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, Ontario, May 12, 1999

Addressing compliance to optimize clinical outcome. A Patient-Based Program in Schizophrenia and Related Psychotic Disorders. Ottawa, Ontario, June 11-12, 1999

What is a novel antipsychotic? Novel Antipsychotics in the New Millennium. State University of New York (SUNY), Syracuse, New York, August 26, 1999

New insights into the pharmacotherapy in early schizophrenia. Search for Treatments in Early Psychosis (STEP): Second Biennial Symposium, University of Pittsburgh, Pittsburgh, Pennsylvania, September 10, 1999

Pharmacotherapy of schizophrenia: from first episode to refractory. Psychopharmacology Update 1999 (sponsored by the Canadian Psychiatric Association). Canadian Psychiatric Association 49th Annual Meeting, Toronto, Ontario, September 14-18, 1999

Optimizing treatment in schizophrenia. Update for Mental Health Care providers. Brandon, Manitoba, September 23, 1999

The psychopharmacology of schizophrenia: where are we? Conference, Real Problems, Real Solutions. Winnipeg, Manitoba, September 24, 1999

Assessment and management of neuroleptic-induced movement disorders. Centre for Addiction and Mental Health, Toronto, Ontario, September 29, 1999

From the lab to clinical practice: what have we learned? Conference, Psychosis: Integrating Research, Education and Clinical Practice to Optimize Outcomes. Third Annual Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, October 1, 1999

A systematic approach to the pharmacotherapy of psychosis (workshop). Conference, Psychosis: Integrating Research, Education and Clinical practice to Optimize Outcomes. Third Annual Atlantic Psychosis Conference, Halifax, Nova Scotia, October 1, 1999

Antipsychotics: from the lab to clinical practice. Grand Rounds, St. Michael’s-Wellesley Hospitals, Toronto, Ontario, November 5, 1999

Pharmacotherapy of schizophrenia: from the lab to clinical practice. Conference, Credit Valley Update: Schizophrenia 1999, Mississauga, Ontario, December 10, 1999

Optimizing treatment in schizophrenia (workshop). Conference, Credit Valley Update: Schizophrenia 1999, Mississauga, Ontario, December 10, 1999

Antipsychotic treatment in schizophrenia: where are we? Grand Rounds, Department of Psychiatry, St. Joseph’s Hospital, Toronto, Ontario, January 18, 2000

Antipsychotics: Exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPP), Centre for Addiction and Mental Health, Toronto, Ontario, January 26, 2000

Pharmacotherapy of schizophrenia: integrating theory and clinical practice. Psychiatry Grand Rounds, Oakville-Trafalgar Hospital, Oakville, Ontario, February 10, 2000

Pharmacotherapy of schizophrenia: where are we? A Problem Based Learning Program in Schizophrenia and Related Psychotic Disorders. Halifax, Nova Scotia, February 12, 2000

Optimizing treatment in chronic schizophrenia. A Problem Based Learning Program in Schizophrenia and Related Psychotic Disorders. (i) Halifax, Nova Scotia, February 12, 2000 (ii) Toronto, Ontario, February 26, 2000

Conventional versus novel antipsychotics: changing concepts and clinical implications

51

(i) Kanazawa University, Kanazawa, Japan, April 7, 2000 (ii) Hiroshima University, Hiroshima, Japan, April 8, 2000

New treatment options for first episode psychosis. Symposium, Recent Changes in First Episode Psychosis. 3rd International Congress of Neuropsychiatry (ICN), Kyoto, Japan, April 9-14, 2000

Current issues in the pharmacotherapy of schizophrenia. Department of Psychiatry, Credit Valley Hospital, Mississauga, Ontario, May 3, 2000

Antipsychotics: from theory to clinical practice. Psychosis: Then and Now. Woodstock, Prince Edward Island, August 12, 2000

Practical issues in long-term antipsychotic use. Workshop, Psychosis: Then and Now. Woodstock, Prince Edward Island, August 12, 2000

Antipsychotics: integrating theory and clinical practice. Royal Ottawa Hospital, Ottawa, Ontario, September 19, 2000

The pharmacotherapy of schizophrenia: making sense of science. !7th Annual Garwood-Jones Lecture, Department of Psychiatry, McMaster University, Hamilton, Ontario, October 11, 2000

Antipsychotics: from PET to clinical practice. Psychiatry Rounds, Wellesley Hospital, Toronto, Ontario, October 13, 2000

Antipsychotic use in the clinical setting. 3rd Annual Ontario Assertive Community Treatment (ACT) Conference, Kingston, Ontario, October 18-20, 2000

Antipsychotics: integrating theory and clinical practice. Department of Psychiatry, McGill University, Montreal, Quebec, November 2, 2000

Psychosis and the new antipsychotics. Primary Care General Psychiatry Course (PCGPC), Centre for Addiction and Mental Health, Toronto, Ontario, November 15, 2000

PET scan and clinical findings with the typical and atypical antipsychotics. Department of Psychiatry, Hotel-Dieu de Lévis, Quebec City, Quebec, November 22, 20

Novel antipsychotics: are they doing better on EPS? Department of Psychiatry, Centre Hospitalier Universitaire Laval, Quebec City, Quebec, November 23, 2000

Antipsychotics: exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPPS), Centre for Addiction and Mental Health, Toronto, Ontario, January 17, 2001

Improving outcome: the role of medication compliance. New Thinking, New Dialogue: An Interactive Program on Schizophrenia and Bipolar Disorder. (i) Hockley Valley, February 23-25, 2001 (ii) Toronto, March 30-April 1, 2001 (iii) Collingwood, June 8-10, 2001

Treatment of refractory schizophrenia. Toronto Psychopharmacology Update Day, Centre for Addiction and Mental Health, Toronto, Ontario, March 10, 2001

Antipsychotics: integrating theory and clinical practice. Psychopharmacology Rounds, Centre Hospitalier Louis H. Lafontaine, Montreal, Quebec, March 26, 2001

The pharmacotherapy of schizophrenia: what’s new? Symposium, Best Practice Guidelines in the Treatment of Schizophrenia. Health Care in a Complex World: an International Research Conference, Toronto, Ontario, May 2-4, 2001

Augmentation strategies. Ontario Government Pharmaceutical and Medical Supply Service: Pharmacists’ Seminar 2001, Toronto, Ontario, May 16-17, 2001 Update on the management of schizophrenia – what’s on the horizon? The 8th Malaysian

Conference on Psychological Medicine. Kuala Lumpur, Malaysia, June 22-24, 2001 Understanding antipsychotics: from PET to clinical practice. Woodbridge Hospital, Singapore,

52

June 25, 2001 Emerging theories on dopamine binding and the selection of antipsychotic agents. Presentation

with Dr. P. Seeman. PsychLINK, Dallas, Texas, July 11, 2001 DSM-IV and the clinical interview. Graduate Seminar in Social Work. Ontario Institute for

Studies in Education (OISE), Toronto, Ontario, September 17, 2001 Current antipsychotic use: integrating PET and clinical data. Department of Psychiatry

Residents’ Retreat, University of Alberta, Calgary, Alberta, September 19, 2001 Fifty years of antipsychotic experience: an update. Claresholm Hospital, Claresholm, Alberta,

September 22, 2001 PET, D2 receptors, and antipsychotic activity: what have we learned?

(i) Department of Psychiatry Rounds, Foothills Hospital, Calgary, Alberta, September 21, 2001 (ii) Department of Psychiatry Rounds, Lougheed Medical Centre, Calgary, Alberta, September 21, 2001

Update on schizophrenia. Dr. F. Jensen Memorial Lecture, A Day in Psychiatry IX (co-sponsored by Department of Psychiatry, University of Western Ontario), Stratford, Ontario, September 28, 2001

Interventions and outcomes: the many faces of schizophrenia. Saskatchewan Schizophrenia 2001 Conference. Department of Psychiatry, University of Saskatchewan, and Schizophrenia Society of Saskatchewan, Saskatoon, Saskatchewan, October 15, 2001

Improving outcome: clinical considerations (workshop). Saskatchewan Schizophrenia 2001 Conference. Department of Psychiatry, University of Saskatchewan, and Schizophrenia Society of Saskatchewan, Saskatoon, Saskatchewan, October 15, 2001

From the PET lab to the clinic: implications for antipsychotic activity. Psychopharmacology Update, Waterford, Ireland, November 10, 2001

Antipsychotics: exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPPS), Centre for Addiction and Mental Health, Toronto, Ontario, January30, 2002

Treatment resistant psychosis. Clinical Challenges in Psychiatric Practice (CCPP), Centre for Addiction and Mental Health, Toronto, Ontario, February 12, 2002

‘Atypicality’, dopamine and serotonin: different means to the same end? (i) Grand Rounds, Douglas Hospital, Montreal, Quebec, February 14, 2002 (ii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, February 15, 2002

What to do in partial responders. Symposium, Treatment-Resistant Schizophrenia. Annual Quebec Psychiatric Association (AMPQ) Meeting, Mont-Tremblant, Quebec, June 6-9, 2002

Translating evidence-based medicine into everyday clinical practice. Symposium, New Directions in Antipsychotic Therapy. XXIII Collegium Internationale Neuro-psychopharmacologicum (CINP), Montreal, Quebec, June 23-27, 2002

Treatment-resistant schizophrenia. ACT Team Psychiatrists, Toronto, Ontario, July 5, 2002 The antipsychotic effect – what is it based upon? Schizophrenia Update, Oslo, Norway,

September 14, 2002 Schizophrenia and treatment-resistance. Grand Rounds, Whitby Mental Health Centre, Whitby,

Ontario, September 20, 2002 Rational psychopharmacology in early psychosis. 3rd International Conference on Early

Psychosis. Copenhagen, Denmark, September 25-28, 2002 The use of antipsychotics in early psychosis. First Episode Psychosis Symposium, Sault Saint

Marie, October 4, 2002

53

Best practice in pharmacological management of first episode psychosis. Workshop, First Episode Symposium, Sault Saint Marie, October 4, 2002

PET and the use of typical and atypical antipsychotics. Symposium: Treatment of the Spectrum of Psychoses. Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002

Tardive dyskinesia: a phantom of the past? Symposium: Treatment of the Spectrum of Psychoses. Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002

Remington G. Antipsychotics: atypicality and mechanisms of action. Plenary Lecture, Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002

Cetkovich M, Crow T, Fleischhacker W, Gaebel W, Duran E, Pfuhlmann B, Remington G. The prodrome of schizophrenia: to treat or not to treat? Debate, Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002

What’s ‘atypical’ about the new antipsychotics? Neuropsychiatry Rounds, University Hospital Network, Toronto Western Hospital, November 28, 2002

Antipsychotics once a day? Theory and evidence. 8th Annual Psychopharmacology Update, Nevada Psychiatric Association, February 13, 2003

How does mechanism of action relate to clinical effectiveness and patient outcomes. Distant Learning Network (DLN) and University of Florida, Cincinnati, Ohio, March 4, 2003

Long-acting depot antipsychotics: where do they fit in? Auckland, New Zealand, March 19, 2003 Novel antipsychotics in depot formulation: research experience and practical considerations.

Modern Management of Psychosis, Sydney, Australia, March 21, 2003 Mothers, molecules and madness. Annual Oklahoma Psychiatric Association Meeting.

Oklahoma City, Oklahoma, April 12-14, 2003 The concept of ‘atypicality’ and its clinical implications. Annual Oklahoma Psychiatric

Association Meeting. Oklahoma City, Oklahoma, April 12-14, 2003 Enhancing antipsychotic effectiveness. Schizophrenia Research Foundation (SCARF), Chennai,

India, May 7, 2003 Re-defining the pharmacological definition of ‘atypicality’. Symposium, Clinical Effectiveness –

What Does It Mean and What’s New. San Francisco. California, May 20, 2003 Antipsychotics 50 years later: what have we learned? Professorial Lecture, Department of

Psychiatry, University of Toronto, Toronto, Ontario, June 10, 2003 The concept of ‘atypicality’: integrating PET data with clinical practice.

(i) Brecksville VA, Brecksville, Ohio, June 17, 2003 (ii) Cleveland Clinic, Cleveland, Ohio, June 18, 2003 (iii) Bridgeway Community Mental Health Clinic, Cleveland, Ohio, June 19, 2003

Antipsychotics 50 years later: what have we learned? Grand Rounds, Toronto General Hospital, Toronto, Ontario, September 19, 2003

Schizophrenia and its prodrome. Sagamore Children’s Centre, Suffolk County, New York, September 23, 2003

The concept of ‘atypicality’: integrating PET data with clinical evidence. Department of Psychiatry Grand Rounds, The Zucker Hillside Hospital, Glen Oaks, New York, September 24, 2003

The early years of schizophrenia. St. Mary’s Children and Family Services, Syosset, New York, September 25, 2003

The evolution of schizophrenia. Department of Psychiatry, Royal Ottawa Hospital, Ottawa,

54

Ontario, October 1, 2003 Antipsychotics: from PET to clinical practice. Royal Ottawa Hospital, Ottawa, Ontario, October

1, 2003 Antipsychotics: integrating theory with clinical practice. Grand Rounds, Department of

Psychiatry, Sunnybrook Hospital, October 10, 2003 Antipsychotics 50 years later: what have we learned? Grand Rounds, Department of Psychiatry,

Mount Sinai Hospital, October 17, 3003 Antipsychotics: mechanisms of action and new treatments. Toronto Advanced

Psychopharmacology Course for Psychiatrists, Centre for Addiction and Mental Health, Toronto, Ontario, October 22, 2003

From response to refractory: the evolution of schizophrenia and its pharmacotherapy. Associations des médicins psychiatres du Quebec. Psychopharmacology Update, Quebec City, Quebec, November 27-29, 2003

The science behind placebo-controlled trials: research methodology and clinical trial design. National Judicial Institute Conference, Research and the Law: A Working Conversation on Scientific Research in the Courtroom. Toronto, Ontario, February 22-24, 2004

Antipsychotic ‘atypicality’: a clinical and moving pharmacological target. Academic Grand Rounds, Allan Memorial Institute, Montreal, Quebec, April 15, 2004

Antipsychotics: a clinical update. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, September 24, 2004

Antipsychotic use: merging theory and science with clinical practice. 10th Annual Conference of the Canadian Academy of Psychiatry and the Law (CAPL). Mont Tremblant, Quebec, February 27-March 2, 2005

Antipsychotic ‘atypicality’: is it just a dopamine story? 8th Annual Meeting, College of Psychiatric and Neurologic Pharmacists, San Diego, California, March 10-13, 2005

First episode schizophrenia: what do we know? 8th Annual Meeting, College of Psychiatric and Neurologic Pharmacists, San Diego, California, March 10-13, 2005

Antipsychotics and dopamine: from receptors to response. Schizophrenia Forum, Oslo, Norway, September 9, 2005

Antipsychotics and schizophrenia 50 years later: what have we learned? Mental Health Grand Rounds, Humber River Regional Hospital, October 14, 2005

Wesson V, Remington G. The CATIE study: results and implications for clinical practice. CAMH Grand Rounds, Toronto, Ontario, October 28, 2005

Adverse event reporting. Conference, Pharmaceutical Research – Review Board and Institutional Challenges, Toronto, Ontario, Nov 4-5, 2005

Treatment of schizophrenia in the community. Conference, Waterford Day. Caring for the Chronic Patient in the Community: Clinical and Ethical Issues. St. John’s, Newfoundland, November 18, 2005

Bottas A, Remington G. Dissecting the CATIE schizophrenia study. Whitby Mental Health Centre, Whitby, Ontario, November 30, 2005

Refractory schizophrenia. Toronto Advanced Psychopharmacology Course for Psychiatrists, Centre for Addiction and Mental Health, Toronto, Ontario, December 7, 2005

Chintoh A, Mann S, Remington G. Schizophrenia, antipsychotics, and weight gain/diabetes. Schizophrenia Program Research Rounds, Centre for Addiction and Mental Health, Toronto, Ontario, December 14, 2005

Schizophrenia and antipsychotics 50 years later: what have we learned. Psychiatry Grand Rounds, University Health Network, Toronto, Ontario, November 3, 2006

Refractory schizophrenia. Toronto Advanced Psychopharmacology Course for Psychiatrists,

55

Centre for Addiction and Mental Health, Toronto, Ontario, December 6, 2006 Antipsychotics 50 years later: what have we learned? Department of Psychiatry Rounds,

University of Ottawa, January 19, 2007 Update on schizophrenia, its conceptualization, and treatment. Resident Seminar, University of

Ottawa, January 19, 2007 Foussias G, Remington G. Was Kraepelin right? Revisiting the negative symptoms of

schizophrenia. Grand Rounds, CAMH, February 2, 2007 Antipsychotics 50 years later: what have we learned? Clinical Neurosciences 2007 Conference,

University of British Columbia, Vancouver, BC, February 23, 2007 Remission in schizophrenia – a false hope? Clinical Neurosciences 2007 Conference, University

of British Columbia, Vancouver, BC, February 23, 2007 Antipsychotics 50 years later: what have we learned? Ontario Working Group on Early

Intervention in Psychosis Conference. Toronto, Ontario, March 2, 2007 Bridging evidence, theory, and clinical experience to optimize antipsychotic response. Grand

Rounds, H omewood Hospital, Guelph, Ontario, May 29, 2007 Antipsychotics 50 years later: what have we learned? World Fellowship for Schizophrenia and

Allied Disorders, 2007 International Conference – Lighting the Path: Hope in Action. Toronto, Ontario, September 29, 2007

The pharmacotherapy of schizophrenia – what have we learned and where do we go? Innovative Horizons: 15th Annual Schizophrenia Conference, Edmonton, Alberta, October 5, 2007

The pharmacotherapy of schizophrenia: do all roads lead to dopamine? Institute of Mental Health Research Rounds, Ottawa, Ontario, November 2, 2007

From Psychology/Biology 101 to the pharmacology of schizophrenia. Plenary lecture, Laurier Student Science Awards 2008, Wilfrid Laurier University, Waterloo, Ontario, February 4, 2008

Ziprasidone: Canada’s newest ‘atypical’ antipsychotic. Remington G, Cohn T. CAMH Grand Rounds, Toronto, Ontario, February 29, 2008

Deconstructing schizophrenia: implications for treatment. Plenary lecture, Alberta Psychiatric Association, Banff, Alberta, April 4-6, 2008

Clozapine-resistant schizophrenia. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, April 25, 2008

Psychopharmacology of schizophrenia (workshop). Schizophrenia 2008 Update, Toronto, Ontario, October 3, 2008

Antipsychotics and glucose dysregulation: from animal models to model animals. Research Rounds, Mood Disorders Program, CAMH, October 16, 2008

Schizophrenia pharmacotherapy: challenges and opportunities. Grand Rounds, McMaster University, Hamilton, Ontario, May 27, 2009

Schizophrenia, dopamine and L-dopa. Multimodal Imaging Group Research Rounds, CAMH, Toronto, Ontario, January 13, 2010

Schizophrenia and functional outcome. National Workshop, Office of the Commissioner of Review Tribunals. Canada Pension Plan (CPP)/Old Age Security (OGA), Toronto, Ontario September 28, 2010

First episode psychosis: presentation, treatment and outcome. Grand Rounds, Department of Psychiatry, Moncton Hospital, September 30, 2010

Antipsychotic pharmacotherapy: from evidence to clinical practice. Grand Rounds, Department of Psychiatry, George Dumont Hospital, October 1, 2010

Schizophrenia and functional outcome. National Workshop, Office of the Commissioner of

56

Review Tribunals. Canada Pension Plan (CPP)/Old Age Security (OGA), Ottawa, Ontario, October 19, 2010

Antipsychotic algorithms. Grand Rounds, Department of Health and Rehabilitation, Hospital Center Division, Essex County Health Center, New Jersey, USA, October 21, 2010

Antipsychotics a half-century later: still a work in progress. 8th Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, November 5, 2010

Antipsychotics: linking theory with clinical practice (workshop). 8th Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, November 5, 2010

Ask the Experts – Antipsychotics. Schizophrenia Update Conference, Toronto, Ontario, November 26, 2010

Schizophrenia a century later: still a work in progress. Schizophrenia Society of Ontario, Annual Staff Meeting, Toronto, Ontario, December 9, 2010

Treating schizophrenia across the lifespan. Psychiatry Grand Rounds, Humber Regional Hospital, Toronto, Ontario, April 115, 2011

The prodrome of schizophrenia and first episode psychosis: treatment outcomes. Moncton Hospital, Department of Psychiatry, Grand Rounds, Moncton, New Brunswick, June 2, 2011.

Treatment algorithms in sczhizophrenia: challenges and opportunities. Psychiatry Rounds, Charlottetown, Prince Edward Island, June 3, 2011.

Schizophrenia and antipsychotics: linking theory and clinical practice. Psychiatry Rounds, Grey-Bruce Health Centre, Owen Sound, Ontario, June 17, 2011

Rodent models: a viable option? Adipogenic and Metabolic Effects of Antipsychotic Drugs (sponsored by NIH and University of Alabama Nutrition and Obesity Research Center), Newark, New Jersey, July11-12, 2011

Remington G, Wong A. First vs. second generation antipsychotics: pros and cons. Psychopharmacology Seminar, CAMH, Toronto, September 21, 2011

Schuchman M, Remington G. Human subject research in psychotic individuals: is it ethical? Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, September 21, 2011

Remington G, Richards S. Facilitating clinical trials. Conference - Getting to Yes: Facilitating Ethical Human Research. Centre for Addiciton and Mental Health, Toronto, Ontario, September 21, 2011

Reconceptualizing schizophrenia: pharmacological challenges and opportunities. Plenary Lecture, Psychosis Day, Department of Psychiatry, University of Calgary. Calgary, Alberta, October 21, 2011

Antipsychotics: optimizing clinical outcome. Workshop, Psychosis Day, Department of Psychiatry, University of Calgary. Calgary, Alberta, October 21, 2011

Remington G, Powelll V. 20 years of clozapine: what have we learned? Schizophrenia Research Day, CAMH, Toronto, Ontario, October 26, 2011

Reconceptualizing schizophrenia: implications for treatment. Grand Rounds, University Hosptial Network (Toronto General), Department of Psychiatry. Toronto, Ontario, November 4, 2011

Psychopharmacology for schizophrenia: lessons from neuroscience (Plenary Lecture). Toronto Psychopharmacology Day, Toronto, Ontario, March 10, 2012

Antipsychotic dosing: found in translation? Innovations in Neuropsychopharmacology Award Lecture. Canadian College of Neuropsychopharmacology, Vancouver, British Columbia, March 24-March 26, 2012

Extended antipsychotic dosing: rationale and clinical findings. Dr. John C. Corrigan Mental Health Center/West Roxbury-Brockton Veterans Administration Medical Center,

57

Department of Psychiatry, Harvard University, United States. May 31, 2012 Antipsychotics and schizophrenia. Schizophrenia Program Resident Seminar, CAMH, Toronto,

Ont, July 12, 2012 Schizophrenia and antipsychotics. Resident Seminar, Schizophrenia Program. CAMH, July 7,

2012 First versus second generation antipsychotics (Albert Wong, Gary Remington). Resident

Psychopharmacology Seminar. CAMH, Sept 19, 2012 Schizophrenia. IMS Graduate Course MSC 1089Y, The Biopsychosocial Basis of Mental Health

and Addictive Disorders, University of Toronto. CAMH, Toronto, Sept 27, 2012 Antipsychotics: linking theory with clinical practice. Cleveland Clinic, Department of Psychiatry

and Psychology Grand Rounds. Cleveland, Ohio, Oct 4, 2012 Update on schizophrenia and antipsychotics. PGY-5 Seminar Series, Department of Psychiatry,

University of Toronto, Toronto, Oct 10, 2012 Schizophrenia and antipsychotics: an update. Canadian Mental Health Association (CMHA),

Brampton, Ontario, Nov 9, 2012 Schizophrenia and antipsychotics: linking theory and clinical practice. Plenary lecture, Victoria

and Vancouver Island Schizophrenia Conference, Victoria, British Columbia, November 16, 2012

From first episode to refractory schizophrenia: optimizing pharmacotherapy. Workshop, Victoria and Vancouver Island Schizophrenia Conference, Victoria, British Columbia, November 16, 2012

Patterns of antipsychotic nonadherence. Reducing the Burden of Chronic Disease in Canada: Innovative Approaches to Disease Management Within Primary Care. Collaborative Forum, CIHR and Pfizer Canada. Ottawa, Ont, Nov 20, 2012

Screening for extrapyramidal side effects. Workshop, Ontario Pharmacists Association: Psychiatric Patient Care Conference, Toronto, Ont, Nov 30-Dec 2, 2012

Antipsychotic dosing: answers found in translation. State University of New York (SUNY) at Buffalo, Grand Rounds, Buffalo, New York, USA, Dec 7, 2012

Subtyping schizophrenia: implications for pathophysiology and treatment. Canadian Assocciation of Psychiatry and the Law (CAPL) Annual Winter Meeting, Mont Tremblant, Quebec, March 4, 2013

Algorithm-based treatment for first-episode schizophrenia. Regina, Saskatchewan, June 12, 2013 Use of treatment response to establish schizophrenia subtypes. Edmonton, Alberta, June 13, 2013 The pharmacology of antipsychotics. University of Toronto, Department of Pharmacy, Year III

Lecture Series, Toronto, Ontario, Sept 17, 2013 First versus second generation antipsychotics. Albert Wong, Gary Remington: Resident

Psychopharmacology Seminar. CAMH, Sept 18, 2013 When in doubt, look at the evidence: investigating high doses and combination treatment

strategies in schizophrenia. Bill Honer, Sumeet Singh, Gary Remington: Symposium, Canadian Psychiatric Association 63rd Annual Meeting, Ottawa, Ontario, September 26, 2013

Remington G, Fellus J. Novel CNS drugs. Cowen and Co., 16th Annual Therapeutics Conference. New York, NY, October 8, 2013

Remington G, Chaiet A, Davies S. Antipsychotic polypharmacy: rational or irrational. CAMH Grand Rounds, Toronto, October 10, 2013

Remington G. Redefining schizophrenia: DSM-V and other new diagnostic approaches. Grand Rounds, Homewood Health Centre, Guelph, October 31, 2013

Remington G. Antipsychotics a half-century later: still a work in progress. Schizophrenia

58

Program Seminar Series, CAMH, Toronto, February 26, 2014 Remington G. Redefining schizophrenia: DSM-V and other new diagnostic approaches.

Psychiatry Rounds, Rouge Valley Centenary Hospital, Toronto, February 26, 2014 Remington G. Best practices for antipsychotic use. Ontario Psychiatric Association 2014 Annual

Conference, Toronto, March 22, 2014 Remington G. Best practices for antipsychotic use. Department of Psychiatry PGY5 Review

Seminar Series, Toronto, September 17, 2014 Remington G. Highlighting schizophrenia’s heterogeneity to personalize treatment (Plenary).

The 8th Annual Pacific Psychopharmacology Conference. Vancouver, British Columbia, September 19, 2014

Remington G. Schizophrenia and its pharmacotherapy. University of Toronto Institute of Medical Science (IMS) 1089H Course, Toronto, September 25, 2014

Remington G. A comparison across two generations of antipsychotics. Department of Psychiatry PGY2 Psychopharmacology Seminar Series, CAMH, Toronto, October 1, 2014

Remington G, Wong A. A comparison across two generation of antipsychotics (Part 2). Department of Psychiatry PGY2 Psychopharmacology Seminar Series, CAMH, Toronto, October 8, 2014

Remington G. Antipsychotics. CAMH Psychopharmacology Seminar Series, CAMH, Toronto, October 16, 2014

Remington G. Antipsychotic update. Professional Specialty Group in Drug Use Evaluation (PSG-DUE). Toronto, Ontario, March 5, 2015

Remington G. Pharmacotherapy in schizophrenia. IMS MSc 10881H - Studies in Schizophrenia, March 25, 2015

Remington G. Antipsychotics: evidence and expectations. Continuing Professional Development Rounds, Department of Psychiatry, University of Western Ontario, April 9, 2015

Remington G. Schizophrenia’s heterogeneity: implications for treatment. Grand Rounds, Douglas Mental Health University Institute, Montreal, Quebec, April 16, 2015

Remington G. Subtyping schizophrenia: implications for pathophysiology and treatment. Grand Rounds, Sacre-Coeur Hospital, Montreal, Quebec, April 17, 2015

E.3. Other Schizophrenia: a journey through turbulence. Schizophrenia Society of Canada, Educational

Video, 1994 New pharmacological agents. Schizophrenia: Biological, Legal & Clinical Perspectives, A

Public Education Series, Schizophrenia Research Program, Clarke Institute of Psychiatry, Toronto, Ontario, April 20, 1994

Co-director, Janssen Canadian Residents Schizophrenia Scholars Program American Psychiatric Association, 149th Annual Meeting, New York, New York, May

4-9, 1996 American Psychiatric Association, 150th Annual Meeting, San Diego, California, May

17-22, 1997 American Psychiatric Association, 151st Annual Meeting, Toronto, Ontario, May 30-

June 4, 1999 American Psychiatric Association, 152nd Annual Meeting, Washington DC, May 15-20,

1999 American Psychiatric Association, 153rd Annual Meeting, Chicago, Illinois, May 13-18,

2000

59

Public Forum, Schizophrenia – Current Research and New Treatments, Sudbury, Ontario, May 11, 1996

Update on schizophrenia. Panel discussion – Schizophrenia Society of Alberta, Calgary, Alberta, June 3, 1996

Co-chair, ACCESS: a national education and consultation program in psychiatry for GP/FPs, 1996-1997

Schizophrenia: an update. FAME (Family Association for Mental Health Everywhere), Etobicoke, Ontario, April 21, 1997

Schizophrenia: new theories and novel antipsychotics. Mens Sana – Families for Schizophrenics, Toronto, Ontario, October 7, 1997

New horizons for schizophrenia. Canadian Mental Health Association, North Bay, Ontario, October 23, 1997

What’s new in schizophrenia research. FAME (Family Association for Mental Health Everywhere), Scarborough, Ontario, October 27, 1997

Update on medications. Schizophrenia Society of Ontario, Scarborough Chapter, Scarborough, Ontario, April 2, 1998

Schizophrenia: what have we learned? Public Health Forum, sponsored by Mental Health Consultation Liaison Service, Grey Bruce Health Services, Owen Sound, Ontario, March 10, 2000

PET and schizophrenia: from the lab to clinical practice. Schizophrenia Society of Ontario, Scarborough Chapter, Scarborough, Ontario, May 3, 2000

Schizophrenia: existing challenges, new opportunities. Schizophrenia Society of Ontario, Burlington, Ontario, May 11, 2011

What’s new in schizophrenia: a brief update. Schizophrenia Society of Ontario, Owen Sound, Ontario, June 16, 2011

Remington G. Conceptualization and diagnosis of schizophrenia: an update. Schizophrenia Society of Ontario (SSO) Annual Board of Directors Meeting, Toronto, June 14, 2014

Remington G. New approaches in the understanding and subtyping of schizophrenia. Schizophrenia Society of Ontario, Toronto, Ontario, September 24, 2014

Healthy Minds Canada Taking Charge 2015: Pathways To Your Own Mental Health Conference Panel discussion: charting treatment (Chair - S Hahaim; Panelists – M Ross, J Geraci, G Remington). Toronto, Ontario, June 20, 2015

F. Teaching and Design F.1 Undergraduate Teaching Teaching

Years

Medical students Years I, II, and III Psychiatry rotation

1984/85 - 1997

Medical students Year I Psychiatry elective

1991/92 - 1997

Schizophrenia, 1993/94

60

Psychiatry Institute of Medical Students Medical students, Year I & II Biology of Schizophrenia, Brain & Behaviour Course Medical Students, Year I

1994/95

Occupational therapy students Year III Psychopharmacology seminars

1985 – 1987

Pharmacy students Year III Schizophrenia and its treatment

1985 – 1987

F.2 Postgraduate Teaching Teaching Years Resident supervision Centre for Addiction and Mental Health

1984/85 - present

Clarke Institute of Psychiatry Residents – Psychopharmacology Seminars

1984/85 – 1991/92

Core Lecture Series, PGY-I & II (a) Psychopharmacology of Schizophrenia (b) Neuroleptic-Induced Side Effects Department of Psychiatry University of Toronto

1991/92 – 1997/98

Psychopharmacology Series Graduate Psychophysiology Seminar York University

1994/95 - 2004

Continuing Care Division Resident Seminars on Schizophrenia

1994/95 - present

Practical Approach to Psychopharmacology Seminar Series: Neuroleptics (PGY-1)

1995/96

Neuroscience and Psychopharmacology Course, PGY-I (a) Antipsychotics I (b) Antipsychotics II Department of Psychiatry University of Toronto

1997/98

Core Program Seminars, PGY-II 1997 - 2000

61

The psychopharmacology of schizophrenia Department of Psychiatry McMaster University Core Curriculum Seminars, PGY-V Psychosis and antipsychotics Department of Psychiatry University of Toronto

2002 - present

Clinical Psychopharmacology Seminars CAMH Residents Program

2004 - present

Schizophrenia & its Psychopharmacology – Graduate Course, Institute of Medical Science (IMS), University of Toronto

2005 – 2008

PGY-II Psychopharmacology Typical vs. Atypical Antipsychotics

2009 - present

G. Graduate Student Supervision Primary Supervisor – Fellows Name: Siow-Ann Chong Program: Department of Psychiatry

Woodbridge Hospital Singapore

Degree: Postdoctoral Research Fellowship Title: Ethnocultural factors in antipsychotic metabolism and clinical

response Years: 1997-1998 Name: Muhammad Fadzillah Abdul Razak Program: Department of Psychiatry

Hospital Kuala Lumpur Jalan Pahang, Malaysia

Degree: Postdoctoral Research Fellowship Title: Antipsychotic dosing strategies based on D2 transience Years: 2002 – 2003 Name: Naren Rao (Co-Supervisor with Dr. Romina Mizrahi) Program: National Institute of Mental Health and Neurosciences

Bangalore, India Degree: Postdoctoral Research Fellowship Tile: Neuroimaging, dopamine and neurocognition Years: 2010-2012 Name: Patrick McCormick Program: University of Toronto Postdoctoral Program Degree: Postdoctoral Research Fellowship Title: The role of the dopamine D3 receptor in motivation and reward

62

Years: 2011-2014 Nsme: Hiroyoshi Takeuchi Program: Keio University

School of Medicine Department of Neuropsychiatry Tokyo, Japan

Degree: Postdoctoral Research Fellowship Title: Extended antipsychotic dosing Years: 2012-2018 Name: Jimmy Lee Program: Woodbridge Hospital, Singapore Program: Postdoctoral Research Fellowship Title: Clozapine-induced neutropenia Years: 2013-2015 Primary Supervisor – PhD Name: Peter Turrone Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title:

The relationship between D2 receptor occupancy and involuntary movements using an animal model

Years: 2001-2003 Name: Araba Chintoh Program: Institute of Medical Science (IMS) Degree: Ph.D. Title: Antipsychotics and Glucose Dysregulation: An Animal Model Years: 2005-2008 Name: George Foussias Program: Clinician/Scientist Program

Department of Psychiatry & Institute of Medical Science (IMS) University of Toronto

Degree: Ph.D. Title: Deficit states in schizophrenia Years: 2007-2013 Name: Margaret Hahn Program: Institute of Medical Science Degree: Ph.D. Title: Antipsychotic-induced glucose dysregulation Years: 2009-2011 Name: Gagan Fervaha Program: Institute of Medical Science, University of Toronto Degree: Ph.D.

63

Title: Evaluating motivational impairments in schizophrenia Years: 2011- Name: Bashrini Madhu (Co-Supervisor) Program: School of Medicine, Sri Lanka Degree: Ph.D. Title: Outcome of patients with schizophrenia: A prospective follow up

study of an incidence and a prevalence cohort Years: 2012- Name: Jennie Pouget Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Investigating the role of immune genes in schizophrenia Years: 2012- Name: Tina Behdinan Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Neuroimaging predictors of functional outcome and social

cognition in schizophrenia Years: 2013- Name: Eric Plitman Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Assessing glutamatergic dysfunction in the associative striatum of

patients with treatment-resistant schizophrenia (TRS) Years: 2013- Name: Mehala Subramaniapillai Program: Department of Exercise Sciences, University of Toronto Degree: M.Sc. Title: Determining the effects of an acute bout of physical activity on

executive function among individuals with schizophrenia Years: 2014- Name: Eric Huang Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: The pharmacogenetics of treatment response in schizophrenia Years: 2014- Name: Ishraq Siddiqui (Co-Supervisor) Program: Institute of Medical Science (IMS) Degree: Ph.D. Title: Behavioural and neurobiological investigation of motivation in

schizophrenia: a focus on novelty, engagement, and social

64

interaction Years: 2015- Primary Supervisor – MSc Name: Jean Kwon Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Compliance in schizophrenia outpatients taking oral antipsychotics Years: 1998-1999 Name: Huma Saeedi Program: Institute of Medical Science Degree: M.Sc. Title: Cognitive and behavioral correlates of D2 transience Years: 2002-2003 Name: Steve Mann Program: Institute of Medical Science (IMS) Degree: M.Sc. Title: Antipsychotic-induced weight gain: an animal model Degree: M.Sc. Years: 2006-2008 Name: Melanie Guenette Program: Institute of Medical Science Degree: M.Sc. Title: Antipsychotic receptor binding and glucose dysregulation Years: 2010-2012 Name: Laura Schulze Program: Institute of Medical Science Degree: M.Sc. Title: Antipsychotic tolerance: an animal model Years: 2012-2014 Name: Joshua Lister Program: Institute of Medical Science Degree: M.Sc. Title: Strategies to reduce antipsychotic-related tardive dyskinesia (TD) Years: 2013-2015 Primary Supervisor - BSc Name: Ishraq Siddiqui Program: University of Toronto

Neuroscience Specialist Co-op Program Degree: B.Sc. Title: Evaluation of novelty exploration and social interaction in

schizophrenia

65

Years: 2012-2013 Name: Sabrina Phan

Neuroscience Specialist Co-op Program Program: University of Toronto Degree: B.Sc. Title: Trajectories and dimensions of response in treatment-resitant

schizophrenia (TRS) Years: 2013 Primary Supervisor – University of Toronto, Department of Psychiatry Clinician Researcher Program Name: Dr. George Foussias Focus: Negative symptoms in schizophrenia Dates: 2004-2009 Name: Dr. Jessica Thoma Focus: Social values in first-episode schizophrenia Dates: 2010-2014 Name: Sr. Suze Berkhout Focus: Adherence in schizophrenia Dates: 2012- Name: Dr. Araba Chintoh Focus: Antipsychotic-related side effects Dates: 2013- Thesis Committees Name: Cynthia Fu Program: Institute of Medical Science (IMS) Title: Noradrenergic dysfunction in the prefrontal cortex in depression:

an [150] H2O PET study of the neuromodulatory effects of clonidine

Years: 1998 – 1999 Name: Ivan Kraljevic Program: Department of Pharmacy, University of Toronto Degree: M.Sc. Title: A cost comparison of typical and atypical depot antipsychotics Years: 2000 – 2002 Name: Joanne Proceviat Program: Dept. of Pharmaceutical Sciences, CAMH Degree: Canadian Hospital Pharmacy Residency (BScPhm) Title: A descriptive analysis of the effectiveness of a pharmacist in the

identification of drug related problems in an outpatient mental health clinic

66

Years: 2000-2001 Name: Livia Martucci Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Dopamine, GABA, and glutamate system genes in schizophrenia Years: 2001 – 2002 Name: April Collins Program: Ontario Institute of Education (OISE), University of Toronto Degree: Ph.D. Title: An educational intervention to enhance awareness of illness and

treatment adherence in schizophrenia Years: 2000 – present Name: Dr. David Mamo Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Aging and neuroleptic sensitivity: a study of aging effects on

relationship between D2 receptor occupancy and catalepsy in rats Years: 2001-2003 Name: Monica Hazra Program: Dept. of Pharmaceutical Sciences, CAMH Degree: Canadian Hospital Residence Pharmacy (BScPhm) Title: Introducing a pharmaceutical-care monitoring tool specific for

antipsychotic emergent diabetes and hyperlipidemia for inpatients at CAMH

Years: 2001-2002 Name: Dr. Tony Cohn Program: Department of Nutritional Sciences, University of Toronto Degree: M.Sc. Title: Diabetes susceptibility in drug-free schizophrenia patients and

metabolic changes after second generation antipsychotics Years: 2004-2006 Name: Edward McAnanama Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Investigating regulation of recall memory in schizophrenia Years: 2006-present Name: Dr. Michele Korostil Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Practice-related learning in schizophrenia: an fMRI investigation Years: 2007-

67

Name: Patrick McCormick Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Pre-clinical evaluation of [11C]-(+)-PHNO as an agonist positron

emission tomography (PET) radiotracer for imaging of the agonist high-affinity, functional state of the dopamine D2 receptor

Years: 2007-2010 Name: Carol Lam Program: Department of Physiology, University of Toronto Degree: M.Sc. Title: CNS nutrient sensing, energy and glucose homeostasis Years: 2007-2009 Name: Rudy Hwang Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Pharmacogenetic analysis of dopamine and glutamate receptor

gene polymorphisms and clinical response to clozapine in patients with schizophrenia

Years: 2008-2013 Name: Ava Elahipanah Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Eye-tracking to examine visual span and visual search selectivity

in schizophrenia Years: 2008-2013 Name: Peter Gorczynski Program: Department of Exercise Sciences, Faculty of Physical Education

and Health, University of Toronto Degree: Ph.D. Title: Dissecting the ‘obesogenic’ environment of CAMH service users Years: 2008-2013 Name: Clair Yang Program: Department of Physiology, University of Toronto Title: Hypothalamic AMPK in the control of glucose production Degree: M.Sc. Years: 2009-2011 Name: Nabilah Chowdhury Program: Institute of Medical Science, University of Toronto Title: Genetics of antipsychotic-induced weight gain Degree: Ph.D. Years: 2009-2014

68

Name: David Greiss Program: Department of Pharmacology, University of Toronto Title: Antipsychotics and increased morbidity in schizophrenia Degree: M.Sc. Years: 2011-2015 Name: Michele Korostil Program: Instittute of Medical Science, University of Toronto Title: Network modulation and learning in schizophrenia Degree: Ph.D. Years: 2011- Name: Philip Gerresten Program: Institute of Medical Science, University of Toronto Title: fMRI and deficit symptoms in schizophrenia Degree: Ph.D. Years: 2011-2015 Name: Tristram Lett Program: Institute of Medical Science, University of Toronto Title: Treating working memory deficits in patients with schizophrenia

using rTMS and genetic prediction of response Degree: Ph.D. Years: 2011-2015 Name: Rachel Rabin Program: Institute of Medical Science, University of Toronto Title: Effects of cannabis abstinence on cognitive function in

schizophrenia Degree: Ph.D. Years: 2012- Name: Danielle Taylor Program: Institute of Medical Science, University of Toronto Title: Antipsychotic response and glutamate system genes Degree: M.Sc. Years: 2012 Name: Mark Duncan Program: Behavioural Medicine, University of Toronto Title: Affective and physiological responses to exercise in patients with

schizophrenia Degree: M.Sc. Years: 2012-2014 Name: Hiren Patel Program: Institute of Medical Science, Univeristy of Toronto

69

Title: Examining cardiorespiratory fitness in diabetic individuals with and without schizophrenia

Degree: M.Sc. Years: 2012-2014 Examination Committees Name: Dr. Albert Wong Program: Institute of Medical Science, University of Toronto Degree: Title:

Ph.D. Identification and analysis of candidate genes for schizophrenia based on the neonatal ventral stiatum.

Year: September, 2001 Name: Dr. Jeff Daskalakis Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Cortical inhibition in schizophrenia Year: July, 2002 Name: Luc Boulay Program: Department of Psychology, Carleton University Degree: Ph.D. Title: Contrasting the effects of haloperidol and olanzapine on attention

and working memory in schizophrenia: a double-blind flexible dose study

Year: April, 2003 Name: Dr. Lashmi Voruganti Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Neuroleptic dysphoria Year: October, 2003 Name: Alison Yung Program: School of Medicine, University of Melbourne Degree: Doctor of Medicine Title: The prodromal phase of schizophrenia and related psychoses:

identification and intervention Year: December, 2003 Name: Francoise Ko Program: Department of Pharmacology, University of Toronto Degree: Ph.D. Title: Is dopamine supersensitivity related to elevated D2 high dopamine

receptors and associated genes in animal models of psychosis? Year: July, 2006 Name: Ava Elahipanah

70

Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Mechanisms of visual search impairment among patients with

schizophrenia Year: January, 2007 Name: Dr. Romina Mizrahi Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Linking phenomenology, anatomy and pharmacology of

antipsychotic treatment Year: May, 2007 Name: Faranak Farazan Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Selective deficits in inhibition of gamma oscillations in the

dorsolateral prefrontal cortex in schizophrenia Year: September, 2008 Name: Dr. Valerie Taylor Program: Department of Psychiatry, McMaster University Degree: Ph.D. Title: Metabolic syndrome in mood disorders Year: December, 2008 Name: Faranak Farazan Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Transcranial magnetic stimulation and electroencephalography on

modulation of gamma oscillations in schizophrenia Year: July, 2010 Name: Mera Barr Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Modulation of gamma oscillatory activity through repetitive

transcranial magnetic stimulation in healthy subjects and patients with schizophrenia

Year: October, 2010 Name: Tracy Bhikram Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Neural circuitry in obsessive compulsive disorder: an fMRI study

of the effect of IV citalopram Year: September, 2012

71

Name: Nina Bahl Program: Institute of Medical Science, University of Toronto Degree: M.Sc. Title: Investigation of neuroplasticity in Parkinson’s disease patients

with chronic deep-brain stimulation Year: December, 2012 Name: Natasha Radhu Program: Institute of Medical Science, University of Toronto Degree: Ph.D. Title: Inhibition of gamma oscillation as a neurophysiological

endophenotype in schizophrenia Year: April, 2015 Name: Mary LaPierre Program: Department of Physiology Degree: M.Sc. Title: Glucagon action in the dorsal vagal complex and the regulation of

glucose homeostasis during high protein-feeding Year: May, 2015 H. Elective Supervisor Name: Iliya Khramov Program/Institution: Undergraduate Program, Summer Award

Dept. of Medicine, University of Toronto, Toronto, Ontario Nature of Elective: Research Title: Health care utilization in patients with schizophrenia maintained

on atypical versus conventional antipsychotics Dates: June – September 2000 Name: Aristotle Voineskos Program/Institution Undergraduate Program, Summer Award

Dept. of Medicine, University of Toronto, Toronto, Ontario Nature of Elective: Research Title: Role of the dopamine D3 receptor in tardive dyskinesia Dates: June – September, 2002 Name: George Foussias Program/Institution: Undergraduate Program, Dept. of Psychiatry

Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia Nature of Elective: Clinical Dates: Sept. 29 – Oct. 17, 2003 Name: Ryan VanLieshout Program/Institution: Undergraduate Program, Dept. Of Psychiatry

Faculty of Medicine, University of Ottawa, Ottawa, Ontario

72

Nature of Elective: Clinical Dates: Nov. 3 – Nov. 23, 2003 Name: Ishpuneet Chhabra Program/Institution: University of Toronto (Scarborough)

Dept. of Psychology - Behavioural Disorders Nature of Elective: Co-Op Dates: September – December 2009 Name: Javaid Naima Program/Institution University of Toronto

Behavioural Biology & Neurosciences Nature of Elective: Animal and Human Drug Trials Dates: November 2009-August 2010 Name: Kathryn McDonald Program/Institution: University of Toronto (Scarborough)

Dept. of Psychology - Behavioural Disorders Name of Elective: Co-Op Dates: January – April 2010 Name: Christopher Tsoutsoulas Program/Institution: University of Toronto (Scarborough)

Dept. of Psychology - Neurosciences Name of Elective: Co-Op Dates: May-August 2010 Name: Larissa Ferguson Program/Institution: University of Toronto (Scarborough)

Dept. of Psychology - Neurosciences Name of Elective: Co-Op Dates: September-December 2010 Name: Cerasela Betlen, MD Program/Institution: University of Toronto, Department of Psychiatry Name of Elective: Psychopharmacology – MAPS Dates: July-December 2011 Name: Serge LeBlanc, MD Program/Institution: University of Toronto, Department of Psychiatry Name of Elective: Psychopharmacology – MAPS Dates: September 2010-June 2012 Name: Araba Chintoh Program/Institution: University of Newcastle, United Kingdom Name of Elective: Undergraduate Selective

73

Dates: April-May 2012 Name: Helen Mik Program/Institution: University of Toronto, Department of Psychiatry Name of Elective: Psychopharmacology – MAPS Dates: September 2012-June 2013 Name: Jonathan Tay Program/Institution: University of Toronto (Scarborough)

Dept. of Psychology Name of Elective: Co-Op Dates: January-August 2013 Name: Daphne Voineskos Program/Institution: University of Toronto, Department of Psychiatry Name of Elective: Psychopharmacology – MAPS Dates: July-December 2013 Gary Remington October 29, 2015